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Abstract 
The peripheral nervous system, unlike the central nervous system, has an exceptional capacity for regeneration following injury. This is due to the remarkable plasticity of the Schwann cells (SC), which are able to reprogramme, following injury, to a progenitor like cell which facilitates peripheral nerve repair. Current knowledge on the molecular basis of this reprogramming is incomplete and we are lacking a global overview of the transcriptional events that occur in SC following nerve injury and how these change over time. 
We aimed to characterise transcriptional changes in the SC, over time, following nerve injury using RNAseq. We also aimed to develop an in vitro dedifferentiation assay to use as a screening tool to asses potential key genes found using RNAseq. 
We developed a method of reliably extracting good quality, SC specific, RNA from the sciatic nerve of mice using fluorescence activated cell sorting. We performed RNAseq on SC from intact nerves and from the distal stump of nerves 6 days post transection. We validated this method by confirming differential expression of genes known to be up and downregulated following nerve injury, using RNAseq data. In analysing the RNAseq data we identified several potentially exciting, novel key molecular players in SC reprogramming, namely Myc and Runt-related transcription factor 1.  
We also developed an in vitro dedifferentiation assay to use as an initial screen for the genes identified using RNAseq. This involved the addition of neuregulin and serum to previously cyclic adenosine monophosphate differentiated SC. This assay was shown to recapitulate the changes seen in vivo, using RNAseq. 
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1. Introduction 
The peripheral nervous system (PNS), unlike the central nervous system (CNS), has an exceptional 
capacity for regeneration following injury. This is due to the remarkable plasticity of the Schwann 
cells (SC), the principle glial cell of the PNS, which is able to reprogramme to a progenitor like cell 
following injury, and functions to facilitate nerve repair. Although our knowledge of the molecular 
events that underlie this process has increased greatly in recent years we are still lacking a global 
picture of the transcriptional changes that occur in SC following nerve injury and how these change 
over time.    
 
1.1 Peripheral nervous system 
The PNS comprises all of the nerves and ganglia outside of the CNS (the brain and spinal cord). It 
serves to connect the CNS to the limbs and organs (motor neurons) and sends signals from these 
back to the CNS (sensory neurons). It can be divided into the somatic nervous system, which controls 
voluntary movements, and the autonomic nervous system which controls unconscious functions 
(Crossman and Neary, 2014). 
 
Nerves in the PNS are either sensory; containing axons and dendrites of afferent, sensory neurons, 
motor; containing axons and dendrites from efferent, motor neurons or mixed; containing both 
sensory and motor neurons (Crossman and Neary, 2014). Each axonal segment in a nerve is 
ensheathed by a SC and surrounded by connective tissue known as the endoneurium, which is 
longitudinally orientated (Sunderland, 1990). Individual nerve fibres are bundled into fascicles by the 
perinuerial connective tissue layer. The epineurium is a connective tissue layer that surrounds 
multiple fascicles to make the nerve trunk proper (Campbell, 2008). The perineurium and 
epineurium are orientated circumferentially (Sunderland, 1990) (Figure 1). 
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Figure 1. Structure of a peripheral nerve. (Adapted from Marieb and Hoehn, 2005.) Image 
reproduced with minor modifications with permission of the rights holder Pearson Education, 
Inc. 
In terms of blood supply, microvessels form plexuses running longitudinally in the epineurium, these 
send transverse processes to the perineurium and the vascular network consists mainly of capillaries 
at the endoneurium (Campbell, 2008).   The PNS is offered some protection by the blood nerve 
barrier (Kanda, 2012). This is found at the microvasculature of the epineurium and at the innermost 
area of vessels of the perineurium (Bell & Waddell, 1984). In these areas the endothelium of the 
vessels are non-fenestrated and endothelial cells are connected by continuous tight junctions. This 
isolates the epineurium from the contents of the blood vessels (Kanda, 2012). Here the endothelial 
cells also express receptors and transporters which aid in the delivery of vital compounds to the PNS 
and removal of toxins from the PNS (Sano et al., 2007).   
 
The PNS, unlike the CNS, is not protected by the bony coverings of the skull or spinal canal leaving it 
exposed to mechanical injury. 
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1.2 Schwann Cell development 
SC are the principal glial cell of the PNS. They originate from neural crest cells in the embryo which 
first differentiate to SC precursors, then immature SC and finally either mature myelinating or non-
myelinating SC (Jessen and Mirsky, 2005). SC are necessary for axonal survival and support. The 
myelin sheath, produced by the SC, insulates the axon allowing fast conduction of action potentials 
along the axon. 
 
Figure 2. Schwann Cell development (Mirsky et al., 2008) The dashed lines indicate 
reversibility. Image reproduced with permission of the rights holder 2005 Nature Publishing 
Group. 
1.2.1  Early SC development 
Le Douarin and Smith’s studies on a bird model showed that most SC are derived from the neural 
crest (Le Douarin & Smith, 1988). Neural crest cells are a temporary group of cells that form from the 
embryonic ectoderm cell layer in vertebrates. The transition from ectoderm to neural crest is 
controlled by bone morphogenic protein (BMP), fibroblast growth factor (FGF) and Wnt signalling 
pathways (Stuhlmiller & Garcia-Castro, 2012). Early in development the neural crest cells split away 
from the dorsal aspect of the neural tube and migrate widely throughout the embryo and proliferate 
to give rise to a wide variety of cell types, including SC. The crest cells originating in the trunk region 
of the neural tube give rise to SC. The fate of the neural crest cells is dependent on both receptor 
signalling and interaction with extracellular matrix (Monk et al., 2015).   
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1.2.2 Schwann Cell Precursors 
Neural crest cells differentiate to SC precursors which are migratory and proliferative, like neural 
crest cells, but differ in the molecular profile and response to signalling. SC precursors express the 
markers Cadherin 19, desert hedgehog (Dhh), Brain fatty acid binding protein (BFABP) and Growth 
associated protein 43 (GAP43) along with low levels of the myelin protein markers myelin protein 
zero (P0), peripheral myelin protein 22 (PMP 22) and myelin proteolipid protein (PLP), these are not 
expressed in neural crest cells (Woodhoo and Sommer, 2008). They associate with axons and rely on 
neuregulin (NRG) 1, via the ErbB2/3 receptor, for survival, unlike neural crest cells whose survival is 
dependent on extracellular matrix (Woodhoo et al. 2004). NRG1 is also essential for proliferation 
and directed migration of SC precursors (Newbern and Birchmeier, 2010). Shah et al found that 
NRG1 was needed for glial specification of neural crest cells and suppressed neuronal differentiation. 
(Shah et al., 1994). It is postulated that the neurotropin 3 (NT3) augments the role played by NRG1; 
as acting via the tyrosine kinase receptor C it stimulates migration of SC and inhibits myelination 
(Chan et al., 2001). Expression of NT3 correlates with the initiation of proliferation in SC and 
decreases when myelination begins (Cosgaya et al., 2002).  The Sry-related HMG box (Sox) 10 
transcription factor is expressed in neural crest cells and SC precursors but is downregulated in other 
cell types derived from neural crest cells (Monk et al., 2015). Mutant animals lacking Sox 10 do not 
have peripheral glia (Britsch et al., 2001; Kelsh and Eisen, 2000).  Sox 10 expression is maintained by 
the transcription factor paired box (Pax) 3, which is activated by the histone deacetylases 1 and 2 
(HDAC 1/2) (Doddrell et al., 2012). Pax3 is also a regulator of the expression of key SC genes P0 and 
Fatty acid binding protein 7 (Fabp7) (Jacob et al., 2014). 
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1.2.3 Immature Schwann Cells 
The differentiation of SC precursors to immature SC is marked by the cessation of migration (Monk 
et al., 2015) and an upregulation of markers such as glial fibrillary acidic protein (GFAP), Sox2 and 
S100β and a downregulation of markers such as cadherin 19 (Jessen and Mirsky, 2005). Woodhoo et 
al. have shown that Notch signalling is key in the SC precursor to immature SC transition (Woodhoo 
et al., 2009).  Immature SC are able to survive in culture, by releasing a cocktail of growth factors 
into the culture media. SC precursors do not have this ability (Jessen and Mirsky, 1997).   Immature 
SC are also able to induce mesenchymal cells to form supporting structures such as vessels, by 
secretion of vascular endothelial growth factor (VEGF) (Mukouyama et al., 2005) and 
perineurial/epineurial sheaths, by secretion of desert hedgehog (Dhh) (Parmantier et al., 1999). Thus 
it is at this point that SC begin to be able to support their own growth and development. 
 
1.2.4 Radial Sorting 
Radial sorting, the process of separating the larger diameter axons from the smaller axons, occurs 
when extracellular matrix proteins have been deposited and organised into basal lamina by 
immature SC. The immature SC’s then make contact with the axons by extending cytoplasmic 
processes, the SC proliferate and separate individual axons from the fascicle (Webster et al., 1973). 
Several small diameter axons are then ensheathed by one non-myelinating SC and are known as 
Remak bundles. Each segment of larger diameter axons form a one to one relationship with a SC, at 
this point the SC stops proliferating and is referred to as a pro-myelinating SC. Once SC have 
acquired the correct relationships with axons they can differentiate into either myelinating or non 
myelinating SC (Monk et al., 2015).  
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1.2.5 Schwann Cell Myelination 
The transition from a promyelinating SC to a myelinating SC is regulated by NRG1; Taveggia et al. 
showed that axonal NRG1 type III is the principal growth factor involved in SC myelination, via the 
ErbB receptor on SC’s (Taveggia et al., 2005). NRG1 acts via the phosphoinositide 3 (PI-3) 
kinase/AKT/ mechanistic target of rapamycin (mTOR) (Hnia et al., 2012), mitogen activated protein 
kinase (MAPK) (Ishiiet al., 2013) and the calcineurin/nuclear factor of activated T-cells (NFAT) (Kao et 
al., 2009) pathways to induce myelination. SC can also control their own myelination via the G 
Protein-Coupled Receptor GPR126 (Mogha et al., 2013; Monk et al., 2009) which increases 
intracellular cyclic adenosine monophosphate (cAMP).    Activation of these pathways results in an 
increase in expression of the transcription factors Sox 10 (Bremer et al., 2011)and Oct-6 
(Bermingham et al., 1996) these act together to induce Krox-20 expression (Jagalur et al., 2011), 
which is considered the ‘master transcriptional regulator of SC myelination’ (Parkinson et al., 2004). 
One of the actions of Krox 20 is to down regulate Notch 1, which is expressed and promotes 
maturation until the onset of myelination (Woodhoo et al., 2009).  
The neurotrophin brain derived neurotrophic factor (BDNF) has been found to promote myelination 
in the early stages via binding to the p75 neurotrophin receptor (p75 NTR), however p75 NTR is not 
expressed by mature SC, and, at later stages, BDNF inhibits myelination (Cosgaya et al., 2002).   SC 
also release the neurotrophin nerve growth factor (NGF) which has been found to stimulate 
myelination in vitro (Chan et al., 2004). 
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1.3 Myelin 
Myelin is the multilayered spiral of specialised cell membrane of the SC (or oligodendrocyte in the 
CNS).  It is made up of 70-85% lipids, (cholesterol, sphingolipids and some more specialised lipids) 
and 15-30% proteins (P0, myelin basic protein (MBP) and PMP22) (Morell and Quarles, 1999). P0 is 
the major protein in PNS myelin (Quarles et al., 2006). The myelin ensheaths the axon with regular 
interruptions known as the nodes of Ranvier, the areas of myelin between the nodes of Ranvier are 
called the internodes. Myelin at the internodes is compact, layers of myelin are fused together, 
whereas myelin adjacent to the nodes is non compact, SC cytoplasm can be found between layers of 
myelin (Scherer, 1996). At the nodes of Ranvier the axon membrane is in contact with the 
extracellular space. Myelin facilitates speed of conduction along the axon as it allows the axonal 
action potential to jump from one node to the next, so called salutatory conduction (Quarles et al., 
2006).  
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1.4 Wallerian Degeneration 
First described by Augustus Volney Waller in 1850 following his observations of frog hypoglossal and 
glossopharyngeal nerves following axotomy, Wallerian degeneration is the process a nerve 
undergoes following a cut or crush injury (Waller, 1850). Wallerian degeneration is seen in both the 
CNS and the PNS. Following injury the proximal and distal ends of the injured nerves retract creating 
a gap between the two ends of the nerve. As the axons distal to the site of injury have lost contact 
with the cell bodies they begin to degenerate. This process is complete within around a day in the 
PNS but takes longer in the CNS (Stoll et al., 2002). This is followed by a period of regeneration. 
Degeneration of the axon is necessary for the regeneration events which follow;  in Wlds mice, a line 
with a spontaneous mutation which causes delayed Wallerian degeneration as the distal axons can 
survive up to 2 weeks following the injury, events such as myelin breakdown, macrophage 
recruitment and axonal regeneration are also delayed (Bisby & Chen, 1990). 
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1.5 Regeneration 
The capability of CNS axons to regenerate following damage is limited but the PNS shows a 
remarkable capacity to regenerate. This is due to the plasticity of the SC, which are able to 
reprogramme following injury. When the axon degenerates, as described above, the SC in the distal 
segment of the nerve loses its axonal contacts. This loss of contact triggers reprogramming of the SC 
to a ‘repair cell’, the features of which I will outline below (figure 3). 
 
 
 
1.5.1 Schwann Cell Dedifferentiation 
Dedifferentiation is the process of a fully differentiated, mature cell reverting to a progenitor cell 
type from its own lineage (Jopling et al., 2011). Classically the SC response to injury has been 
described as a dedifferentiation response (Chen et al., 2007), although it is now known that this is 
Figure 3. Changes seen in SC following nerve injury. (Adapted from Lee et al., 2014.) 
Image reproduced with minor modifications with permission of the rights holder 
Experimental Biology 2014. 
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only part of the vast array of changes seen in the SC following nerve injury. The terminally 
differentiated myelinating SC provides support to the axon and insulates the axon, propagating the 
speed of the signal down the axon. To provide this function the key genes in mature SC are those 
coding for the myelin protein machinery such as the transcription factor Krox 20, the master 
regulator of myelin transcription, myelin associated  proteins such as P0, myelin basic protein (MBP), 
PMP and PLP, enzymes involved in cholesterol synthesis and membrane associated proteins such as 
periaxin.  These genes are all quickly downregulated when SC become denervated (Chen et al., 2007; 
Jessen & Mirsky, 2008). Accompanying this is an upregulation in genes associated with an immature 
SC phenotype; sox 2, p75NTR, L1, neural cell adhesion molecule (N-cam) and glial fibrilary acidic 
protein (GFAP) (Chen et al., 2007; Jessen and Mirsky, 2008). Thus following injury the SC changes 
gene expression profile to resemble an immature SC, therefore undergoes dedifferentiation, 
although SC also acquire other properties not shared by immature SC as described below. These 
changes in gene expression begin within 48 hours of nerve injury (Trapp et al., 1988; White et al., 
1989).  
 
1.5.2 The Schwann Cell Repair Programme 
Following injury there is also upregulation of genes not active during SC development. Most striking 
is the transcription factor cJun; in cJun knockout mice peripheral nerve regeneration is severely 
compromised whereas development of the peripheral nerve proceeds normally (Arthur Faraj et al., 
2012).  
 
There is upregulation of genes that code for proteins which assist in repairing the nerve and 
recruiting inflammatory cells to the wound site. N-cadherin, BDNF, glial cell line derived 
neurotrophic factor (GDNF), artemin, NT3, erythropoietin, VEGF and pleiotrophin are all factors 
which promote axonal growth and elongation (Boyd and Gordon, 2003). These factors are all 
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upregulated in SC in the distal stump following nerve transection; artemin is not expressed in SC 
during development (Fantana et al., 2012) and GDNF and N-cadherin, are expressed in the SC 
precursor but not in the immature SC during development (Jessen and Mirsky, 2005).  
 
The SCs in the distal segment of the nerve following injury also release a cocktail of cytokines that 
attract and activate inflammatory cells, particularly macrophages, to the wound site, these include 
tumour necrosis factor (TNF) alpha, leukaemia inhibitory factor (LIF), and interleukin (IL) 6. Some of 
these cytokines also promote axonal regrowth (Bauer et al., 2007).  
 
A microarray study comparing the sciatic nerve distal to a crush injury to intact developing and adult 
sciatic nerves, identified over a hundred genes that were differentially regulated between intact and 
crushed nerves that were not developmentally regulated (Bosse et al., 2006), this suggests that the 
SC response to injury is not purely a dedifferentiation response.  
 
1.5.3  Myelin Clearance 
During the first 5-7 days following nerve transection the SC are principally responsible for myelin 
clearance and about half of the myelin is cleared in this time period (Perry et al., 1995). Although the 
mechanism of clearance that the SC use has previously been described as phagocytosis (Stoll & 
Muller 1999; Hirata & Kawabuti, 2002.) this is not strictly correct as the term phagocytosis applies 
only when something external to the phagocytic cell is internalised and digested, whereas following 
nerve transection there is no evidence that the myelin ever breaks away from the SC before being 
digested. It has been shown that myelin breaks up within the SC into oval shaped fragments which 
are then processed into smaller myelin segments, this is dependent upon actin polymerisation (Jung 
et al., 2011). These myelin segments are then digested in lysosomes in a process known as 
autophagy (Gomez-Sanchez et al., 2015). Following this initial SC phase of myelin clearance, a second 
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phase, which is much more dependent on macrophages proceeds. The macrophages phagocytose 
myelin debris (Mosley and Cuzner, 1996). 
 
1.5.4 Axonal Guidance 
Another key function of the reprogrammed SC  is its ability to guide axons to their distal targets, a 
feature not seen in the developmental setting where axons are able to migrate to their innervation 
target in the absence of glial cells (Grim et al., 1992) in fact during development the SC follow the 
axons to the target (Heerman & Schwab, 2013) until the late stages when it is suggested the SC may 
influence the growth of axons (Gilmour et al., 2002; Morris et al., 1999; Nguyen et al., 2002).  
Following injury the SC change morphologically; they elongate and form channels, known as bands 
of Bungner, which guide the axons from the proximal nerve towards the distal stump, these are first 
seen around 4 days following nerve injury (Svennigsen and Dahlin, 2013).  
 
Fibroblasts accumulate at many injury sites where they secrete extracellular matrix and contribute 
to scar formation as well as secreting cytokines which mediate inflammation and angiogenesis, but 
in respect to peripheral nerve injury Parrinello et al. have shown they also play a key role in guiding 
SC migration. Ephrin B on fibroblasts binds to the EphB2 receptor on SC to trigger a switch in the SC 
from repulsion to attraction thus allowing the SC to form bands of SC which bridge the gap between 
the nerve ends. The transcription factor Sox 2 has been found to be a downstream target of the 
EphB2 receptor and activation causes relocalisation of the transmembrane protein N-cadherin, 
which mediates cell-cell adhesion, to the SC contacts. These bands of SC are necessary to guide the 
axons back to the distal target; disruption of these SC bands result in disruption of axonal re-growth 
(Parrinello et al., 2010). Recently Cattin et al. have shown that newly formed blood vessels, formed 
in the nerve bridge in response to VEGF released from hypoxic macrophages, act as a scaffold for the 
SC to migrate across with axons following (Cattin et al, 2015). 
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1.5.5 Proliferation 
In contrast to the mature myelinating SC which is quiescent and forms a 1:1 relationship with an 
axon segment, following injury SC proliferate in order to replace lost or damaged tissue following 
nerve injury. In development, SC stop proliferating at the promyelinating SC stage. Proliferation of 
the SC is facilitated by the release of mitogens by macrophages at the injury site (Davies & Stoobant, 
1990) and the peak rate of SC proliferation is seen 2-3 days after nerve injury (Clemence et al., 
1989). The work of Monje et al.’s in vitro has suggested that the initiation of proliferation is not 
regulated by the same genes that cause the other changes that occur in the SC following nerve injury 
(Monje et al., 2010.) suggesting that proliferation is uncoupled from dedifferentiation in SC. It has 
been shown that SC proliferation is not necessary for peripheral nerve regeneration as mice with SC 
that don’t have the ability to proliferate still have normal nerve regeneration following crush injury 
(Yang et al., 2008). 
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1.6  Reinnervation 
If the regenerating axons make contact with the distal targets the SC then differentiate and 
remyelinate the axon (Sulaiman and Gordon, 2009). In these remyelinated nerves the myelin sheath 
is thinner than prior to injury and the length of the internodes is shortened which leads to a slower 
speed of conduction of the axonal signal in the remyelinated area (Sherman and Brophy, 2005).  
If, however the regenerating axons do not make contact with the intended end target, the SC 
forming Bands of Bungner at the distal stump will disappear and eventually be replaced by scar 
tissue (Hall, 1999). If repair is delayed there is a significant increase in SC apoptosis (Saito et al., 
2009). Over time SC lose the ability to promote axonal regeneration, although it seems that 
chronically denervated SC still retain the ability to re-differentiate to myelinating SC upon axonal 
contact (Sulaiman and Gordon, 2000). It has been found that the neuron is able to attempt 
regeneration for at least 12 months after injury (Campbell, 2008). SC in culture can undergo multiple 
cycles of differentiation/dedifferentiation (Monje et al., 2010) 
 
 
 
 
 
 
 
 
 
 1.7  Molecular basis of SC reprogramming following injury
Although we are lacking a global picture of the transcriptional changes that occur in SC following 
nerve injury, there have been several key molecular 
that occur in the SC following nerve injury
 
 
1.7.1 MAPK cascades 
a)  Ras/Raf/ extracellular signal
The Ras/Raf/ERK intracellular signalling pathway has been found to be of importanc
were forced to express Raf kinase showed features consistent with a demyelinating phenotype and 
activation of Raf alone was found to be sufficient to cause SC to dedifferentiate in the absence of 
nerve injury, it also caused macrophage recrui
has also been shown to occur in vitro; SC in culture respond to cAMP by differentiation; increasing 
expression of several myelination genes including P0, Krox 20 and MBP (Morgan et al., 1991) but SC 
Figure 4. Overview of the key molecular players involved
are shown in red, signalling pathways in blue, transcription factors in green and the results 
of activation of the transcription factors or receptors are shown in boxes. Arrows indicate 
activation. 
Dedifferentiation
25 
  
players identified which regulate the changes 
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-regulated kinases (ERK) 
tment and SC proliferation (Napoli et al. 2012). This 
 in SC dedifferentiation. Receptors 
 Dedifferentiation 
Dedifferentiation 
 
e; mice which 
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over-expressing Raf kinase were resistant to this cAMP induced differentiation (Harrisingh et al. 
2004). cJun and notch signalling are thought to be downstream of Raf (Napoli et al., 2012). In SC 
induced to express Ras, in vitro, differentiation was inhibited and dedifferentiation was induced 
(Harrisingh et al 2004). Signalling via both Raf and Ras was found to be ERK dependent (Harrisingh et 
al 2004, Napoli et al. 2011). High levels of ERK activation have been seen at both the proximal and 
distal nerve ends within hours of nerve injury (Sheu et al. 2000). Inhibition of ERK prevented SC 
proliferation, cytokine release and demyelination in vivo but even when ERK is inhibited p75NTR, a 
SC dedifferentiation marker, is still expressed and expression of myelin protein genes is reduced  
(Napoli et al., 2012; Shin et al., 2013) suggesting other factors are in play.  
 
b)  Rac/JNK 
c-Jun N-terminal kinases (JNK), which are activated by MAP kinase kinase 7 (MKK7), cause expression 
of cJun; this has been found to play a role in the dedifferentiation of SC in culture when cAMP is 
removed (Monje et al., 2010). JNK was also found to activate cJun in ex-vivo nerves (Shin et al., 
2013).  
Rac is upstream of JNK and has been shown to be activated in SC following nerve injury (Jung et al., 
2011) and play a role in demyelination (Park & Feltri, 2011).  
 
c)  p38MAP Kinase 
p38MAPK activation in vitro was found to induce dedifferentiation, block cAMP activated 
differentiation and mediate myelin break down. It was also found to induce expression of cJun. P38 
MAPK activation occurs within minutes of nerve injury in the distal part of the injured nerve (Zrouri 
et al., 2004). Inhibition in vivo was found to block dedifferentiation of SC following nerve injury (Yang 
et al. 2012).   
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Despite the above, around 60% of gene expression changes in SC following nerve injury occur 
independently of MAPK’s (Shin et al., 2013). 
 
1.7.2 Transcription factors 
a)  C-Jun 
Mice with a conditional deletion of the transcription factor cJun were shown to have delayed loss of 
myelin proteins, abnormal morphology of the Bands of Bungner, reduced survival of neurones, and 
delayed functional recovery following nerve injury when compared to wild type mice. (Arthur-Farraj 
et al. 2012; Parkinson et al., 2008).  These mice had normal nerves suggesting cJun is not a key 
player in developmental regulation (Arthur-Farraj et al., 2012). 
It has been suggested that one of the key roles of cJun is to suppress krox 20 expression (Parkinson 
et al., 2004) as cJun is known to have a cross inhibitory relationship with the myelin transcription 
factor krox 20 (Parkinson et al., 2008), in that expression of one inhibits expression of the other. cJun 
is also fundamental in regulating the expression of neurotrophic factors such as GDNF, artemin and 
BDNF, as SC lacking cJun expression fail to release these factors which are essential for axonal 
survival (Fontana et al., 2012). 
 
b) Sox 2 
Inducing expression of the transcription factor Sox2 in vitro was found to inhibit the SC 
differentiation which is usually seen with the addition of forskolin, a cAMP analogue, to the culture, 
the SC remained in a dedifferentiated state and showed increase in proliferation rates in response to 
mitogens (Le et al., 2005). As described above, Sox2 is also fundamental in formation of bands of 
Bungner which are key in axonal guidance (Parrinello et al., 2010). 
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1.7.3  Growth Factors 
a)  NRG1  
Treatment of SC / dorsal root ganglion (DRG) co-cultures with NRG1 induced a reduction in myelin 
protein genes and an increase in genes associated with immature SC (Zanazzi et al., 2001). Inhibiting 
the ERK pathway in the NRG1 treated cells resulted in reduced cJun expression and prevented 
demyelination (Syed et al., 2010). This suggests that a function of NRG1 is to act via ERK to activate 
cJun, although reports from in vivo and ex vivo experiments suggest that cJun expression is not 
controlled by ERK (Shin et al., 2013; Monje et al., 2010).  
 
In other in vivo studies NRG1 has been found to activate three of the MAPK’s (p38 MAPK, JNK and 
ERK) and hence regulate cJun expression, if any of the three MAPKs were inhibited the 
demyelinating effects of NRG1 were not seen (Harrisingh et al., 2004; Yang et al., 2012). Adding 
NRG1 to injured nerves facilitated the repair of the nerves (Chen et al., 1998).  
 
b)  Transforming growth factor (TGF) beta 
TGF beta has been shown to cause proliferation of SC in vitro when used in combination with NRG1, 
however if NRG1 is not present an increase in apoptosis of SC is seen, a reduction in the number of 
SC undergoing apoptosis following nerve injury was also seen in vivo in mice with a deletion of the 
type II TGF beta receptor in SC (D’Antonio et al., 2006). TGF beta has also been shown to inhibit 
myelination of SC in vitro (Einheber et al., 1995).  
 
c)  Fibroblast Growth Factor (FGF) 2 
Zanazzi et al have shown that addition of FGF-2 to SC/neuron co-cultures inhibits myelin formation 
(Zanazzi et al., 2001). FGF-2 also inhibits cAMP induced differentiation in vivo (Morgan et al., 1994). 
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1.7.4  Receptors 
a)  Notch 
The transmembrane receptor protein Notch has also been implicated as a key player as loss of Notch 
in vivo was found to impede SC dedifferentiation after nerve injury and expression of Notch was 
found to promote SC dedifferentiation in intact nerves (Woodhoo et al. 2009).  
 
b)  Netrin  
Work by Webber et al., published in 2011 showed that the balance of expression of the netrin 1 
receptors deleted in colorectal cancer (DCC) and Uncoordinated (Unc)5H2 also play roles in 
peripheral nerve repair. In mature myelinating SC the expression of the inhibitory receptor Unc5H2 
predominates. Following injury there is upregulation of the axonal growth promoting receptor DCC 
and inhibition of expression of the Unc5H2 receptor. When expression of DCC was inhibited in the 
injured nerve in vivo axonal regeneration was impaired and expression of Unc5H2 was increased. 
When the Unc5H2 was inhibited axonal growth was facilitated. These changes were independent of 
levels of netrin 1 (Webber et al., 2011). 
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1.8 Clinical Relevance 
SC are key in several important pathological conditions; 
1.8.1 Peripheral nerve injury  
Peripheral nerve injury is a relatively common problem affecting 20 million people (Grinsell & 
Keating, 2014) and costing around $150 billion annually in the US (Taylor et al., 2008). The most 
common cause of peripheral nerve injury is trauma, 3% of trauma cases incur a peripheral nerve 
injury, and most injuries occur in the upper limb (Kouyoumdjian, 2006; Svennigsen and Dahmin, 
2013). Peripheral nerve injury can result in significant morbidity for the patient with loss of motor 
and/ or sensory function of the organ/s the affected nerve innovates and neuropathic pain can also 
be a significant problem. The psychological impact of these issues can be catastrophic for the patient 
(Rosberg et al., 2005). 
 
a)  Classification 
Peripheral nerve injury can be classified, according to the amount of disruption to the nerve, by 
either the Seddon or the Sunderland classification systems (see table 1) (Seddon, 1943; Sunderland, 
1951.) Of these the Sunderland classification is more robust. 
Sunderland Seddon Description 
I Neurapraxia Conduction block. Demyelination. 
II Axonotmesis Axonal loss. 
III  Disruption of the endoneurium. 
IV  Disruption of the perineurium. 
V Neurontomesis Disruption of the epineurium. 
Table 1. The Sunderland and Seddon Classifications of peripheral nerve injury. 
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 The mildest of these nerve injuries is neuropraxia (Sunderland grade I) where the axons remain 
intact but there is loss of function of the nerve, usually due to compression. Wallarien degeneration 
does not occur in this setting and assuming the cause of the injury has resolved normal function of 
the nerve can be expected from within a few hours to within a few months, with the average 
neuropraxia injury taking around 12 weeks to recover from (Dumitri et al., 2001). 
 
Disruption of the axon occurs when the injury is more severe such as lacerations, contusions, 
stretching or severe compression of the nerve. In these cases Wallerian degeneration does occur. In 
axonotomesis injuries where there is preservation of the surrounding stroma (Sunderland Grade II), 
the recovery time and extent depends on the amount of axonal disruption and the distance of the 
axon from its end target, but recovery is usually complete (Campbell, 2008). In neurontomesis 
(Sunderland Grade V) there is complete loss of continuity of the nerve trunk and disruption to the 
surrounding tissues, reinnervation is not possible and without surgery the prognosis is very poor 
(Campbell, 2008).  In any injury classified as Sunderland Grade III or above, the recovery time is likely 
to be long and the recovery is, more often than not, incomplete (Sunderland, 1978).    
 
b)  Treatment 
The first nerve repair was documented in the 7th Century by a military surgeon, Paulus Aegeneta 
(Griffin et al., 2014). Since then much of the advancement in peripheral nerve surgery has been on 
the battle fields. Current options for surgical repair of peripheral nerves include either reattaching 
the two ends of the cut nerve together, neurorrhopy, or attaching the two ends of the nerve 
together with a graft, this is favourable if neurorrhopy would place the nerve under too much 
tension.  
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The timing of the surgery can be described as either primary, where surgery takes place within a 
week of the injury to the nerve, or secondary, where surgery to repair the nerve takes place at any 
time after a week after the damage (Payne, 2001).  Results of surgery are much improved in primary 
rather than secondary repair, but a surgeon may advocate waiting for up to 10 weeks to see if the 
nerve spontaneously recovers function; it is known that axons grow at a rate of 1-3mm per day 
(Deumens et al., 2010) which can aid the decision of whether surgery is necessary or not. Primary 
repair may also not be possible in some cases where compromise to other systems, such as fracture 
of the bone or vascular compromise, may be more urgent. Surgery should result in well aligned, 
healthy nerve fascicles, with a good vascular supply and under minimal tension, if this can not be 
achieved in the acute setting then secondary repair may be preferable (Payne, 2001).  
 
In only around half of cases does the surgical repair result in a satisfactory outcome (Thomson, 2005) 
and more favourable outcomes have been found when the patient is younger and when the injury is 
more distal (Grinsell & Keating, 2014). 
 
There has been significant advances in the knowledge of the molecular biology underpinning 
peripheral nerve repair and several studies have shown improvement in peripheral nerve repair by 
targeting these molecular mechanisms in small mammals, but there is still no therapy of this nature 
available to humans suffering from traumatic nerve injury (Hoke, 2006). Promising results have also 
been seen in animal studies when SC are transplanted into nerve conduits, these effects can be 
enhanced when the SC are modified to increase expression of growth factors (Li et al., 2006; May et 
al., 2008). Despite this the gold standard treatment of epineurial repair surgery for peripheral nerve 
injury has changed little in the last 25 years. 
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1.8.2 Peripheral Neuropathies 
Peripheral neuropathy describes a wide range of conditions that affect peripheral nerves and result 
in impaired sensation, movement and/or organ function. The causes are wide ranging and include 
systemic disease (such as diabetes and HIV), iatrogenic causes (such as chemotherapy), hereditary 
conditions and trauma. They can be classified as axonal or demyelinating depending on the nature of 
the pathology seen; axonal neuropathies involve degeneration of axons and demyelinating 
neuropathies are caused by dysfunctional SC, although these two pathologies overlap in most cases 
usually one predominates (Feldman et al., 2008). A small pilot study looking at cJun expression in 
neuropathies found that expression was markedly increased in SC in patients found to have axonal 
neuropathies and was also found to be upregulated in SC in demyelinating neuropathies (Hutton et 
al., 2011), suggesting a similar process to that occurring in SC following injury. Below I will highlight 
some of the areas research into this condition has focused on.   
 
a) Human immunodeficiency virus associated distal sensory polyneuropathy (HIV-SN) 
This peripheral neuropathy affects 10-35% of people with HIV (Cornblath & Hoke, 2006; McArthur et 
al., 2005; Sacktor, 2002). Degeneration of small distal nerve fibres and recruitment of HIV infected 
macrophages to the dorsal root ganglia are seen microscopically. It is thought to be caused by 
mediators released by HIV infected macrophages rather direct infection of SC by HIV and many cases 
are thought to be due to toxicity of antiretroviral medication. A trial in 1996 tested the effects of 
recombinant NGF on patients with HIV-SN, although promising results were seen in terms of pain 
reduction many side effects were reported (McArthur et al., 2000; Schifitto et al., 2001).  
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b)  Charcot Marie Tooth Disease (CMT) 
CMT is a class of hereditary neuropathy which commonly presents in the first and second decade of 
life with balance difficulties, clumsiness and distal muscle weakness. It has a worldwide prevalence 
of around 1 in 2500 and is usually inherited in an autosomal dominant fashion (Irobi-Devolder, 
2008).   There are several subtypes, CMT1 is demyelinating and CMT2 is axonal.  The most common 
subtype is CMT1A where sufferers have three copies of the PMP22 gene and therefore over-express 
PMP22 leading to dysfunctional myelin production. Other subtypes of CMT1 are caused by loss of a 
copy of the PMP22 gene, mutations in the genes coding for PMP22, Krox 20 and P0, which lead to SC 
dysfunction (Suter and Scherer, 2003).  
 
Observations in the mouse model of CMT1A have found that there is increased autophagy in the SC 
(Gomez-Sanchez et al., 2015). When human SC carrying a mutation in PMP22 gene were grafted into 
nude mice the injured nerve failed to regenerate in the area of the graft indicating that the abnormal 
SC also affected the axon (Sahenk et al., 1999) when the mice were treated with the NT3 axonal 
regeneration was improved (Sahenk et al., 2005).  Given these findings Sahenk et al. went on to test 
NT3 treatment in a small number of CMT patients; the patients were treated with either NT3 or 
placebo for 6 months and patients who received NT3 were found to have a higher density of 
myelinated nerve fibres on nerve biopsy and improved sensory functions when compared to those 
receiving placebo, this was not seen when it came to motor functions (Sahenk et al., 2005). SC in a 
mouse model of CMT1a were found to have increased expression of cJun, which is thought to 
protect from loss of axons, as when cJun was inactivated there was an increase in axonal loss 
(Hantke et al., 2014). 
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c)  Diabetic Neuropathy 
Diabetic neuropathy is the most common peripheral neuropathy in developed countries (Said, 2007) 
and affects 13-40% of diabetic patients (Zochodnene, 2007).  It is characterised by axonal loss, 
demyelination, remyelination and vessel changes (Behse et al., 1977). It is thought to be caused in 
part by ischaemic damage to the nerves, and by increased glucose metabolism via the polyol 
pathway. In vitro studies have shown that activation of this polyol pathway in SC leads to a reduction 
in NGF production. Replacement of NGF in diabetic neuropathy showed promising results in phase II 
clinical trials (Apfel et al., 1998) but the phase III clinical trials did not replicate these findings (Apfel 
et al., 2002).    
   
1.8.3 Peripheral Nerve Sheath Tumours   
Peripheral nerve sheath tumours (PNST) are a group of tumours that arise from the cells in a 
peripheral nerve. They range from benign neurofibromas, schwannomas and perineuromas to 
malignant peripheral nerve sheath tumours (MPNST), and can occur spontaneously or be associated 
with the hereditary, autosomal dominantly inherited disease, neurofibromatosis (NF). NF1 is caused 
by a mutation of the NF 1 gene on chromosome 17 and patients have multiple neurofibromas and 
less commonly, MPNSTs. NF2 is caused by a mutation of the NF2 gene on chromosome 22 and this is 
associated with an increased incidence of schwannomas (Mertens and Lothe, 2001).  MPNST are 
relatively rare, account for 5-10% of all malignant soft tissue tumours, 50% are in patients with NF1 
(Geller and Gebhardt, 2006).  
 
Neurofibromas, schwannomas and some MPNST arise from SC.  In neurofibromas of NF1 patients 
the timing of the mutation of the NF1 gene during development of the SC is critical; in a mouse 
model, NF1 loss at the late SC precursor/early immature SC stage resulted in neurofibroma 
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development whereas neurofibromas did not occur in peripheral nerves if loss was later in the 
immature SC stage (Joseph et al., 2008; Wu et al., 2008; Zaheng et al., 2008).  It is suggested that the 
loss of SC/axon interaction is key for the development of this tumour. In axon/SC co-cultures loss of 
NF1 in the SC induced dissociation from axons due to a down regulation in the SC surface protein 
semaphorin 4F via the Ras-Raf-ERK pathway (Parrinello and Lloyd, 2009). This loss of axonal contact 
allows the SC to become more responsive to mitogens and, therefore, become more proliferative 
(Parrinello and Lloyd, 2009). The stroma of neurofibromas tend to contain numerous inflammatory 
cells, specifically mast cells, it is thought that the factors realised by these inflammatory cells provide 
a favourable environment for tumour progression (Le and Parada, 2007) these mast cells have been 
found to contain the same NF1 mutation as the SC (Yang et al., 2008). Parallels can be drawn 
between the loss of axonal/SC contact, SC proliferation and inflammatory environment seen 
pathologically in neurofibromas and physiologically following peripheral nerve injury. Similar 
parallels can be made in the case of schwannomas; vestibular schwannommas with NF2 gene 
mutations were found to have reduced expression of myelin proteins and increased expression of N-
Cam, NGFR and L1, resembling a denervated SC following nerve injury (Hung et al., 2002).    
Activation of NRG/erbB signalling has been found to be increased in neurofibromas and MPNST 
(Stonecypher et al., 2005) as well as schwannomas (Stonecypher et al., 2006). 
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1.9 Aims  
While the work outlined above has identified some of the key players involved in SC reprogramming 
following nerve injury our knowledge of the mechanisms that initiate and maintain these changes in 
the SC are still incomplete and fragmented. A systems level, global approach is now needed to fully 
understand the mechanisms behind the changes seen in SC following nerve injury. 
 
Unpinning these changes will lead to improved understanding of the complex process of repair 
following nerve injury. As well as furthering our knowledge on the complex process of peripheral 
nerve regeneration this may also provide important targets for improving nerve regeneration 
therapy and may also provide potential therapeutic targets for treatment of peripheral neuropathies 
and peripheral nerve sheath tumours, subtypes of which are characterised by aberrant SC 
dedifferentiation.  
 
The aims of this project are  
 To characterise the global transcriptional changes that occur in SC following 
nerve injury, over time, using RNAseq. 
 To develop an in vitro dedifferentiation assay to provide an initial screen for 
analysing potential key genes found by RNAseq. 
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2. Materials and Methods 
2.1 In Vivo Methods 
 
2.1.1 Animal housing conditions 
All animal work was carried out in accordance with the guidelines and regulations set out by the 
Home Office. Animals were housed in social groups where possible and environmental enrichment 
was available in all cages. Animals were kept in rooms at a constant temperature and maintained on 
a twelve hour light/dark cycle. They were fed on standard rodent chow and water ad libitum. The 
animals were identified by ear notch. 
 
2.1.2 Mouse line 
We had available mice from the B6.Cg-Gt(ROSA)26Sortm14(CAG-tdTomato)Hze line from The Jackson 
Laboratory, these mice have a loxP flanked STOP cassette at the Ai14 conditional allele which 
prevents transcription of the downstream red fluorescent protein Td Tomato. These mice were 
crossed with mice from the line B6N.FVB-Tg(Mpz-Cre)26Mes/J, also from The Jackson Laboratory, 
which expressed Cre recombinase under the control of P0. This resulted in the STOP cassette being 
deleted in P0 expressing tissues, i.e. SC, and expression of the tdTomato in the SC of the offspring. 
The Cre expression in the mouse line is also seen in a small number of periventricular cells giving rise 
to cortical cells and in a subpopulation of neural crest progenitors found in the heart, as our work 
looks solely at the peripheral nerves the expression in these cells will not confound our results.    
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2.1.3 Genotyping 
The ear notches taken from the mice for identification were used to extract DNA for genotyping the 
mice. To do this the ear notches were placed in 600µl of sodium hydroxide and boiled at 95°C for 10 
minutes. 100µl of Tris-HCl was added to each sample. 
 
The polymerase chain reaction (PRC) mix for each sample was made up of the following: 
5µl 5x Taq buffer (Promega) 
2µl magnesium chloride (Sigma-Aldrich) 
0.5µl Deoxynucleotide (dNTP) solution (New England BioLabs) 
1 µl Primer (see table 2) 
0.2µl Go Taq DNA polymerase (Promega) 
15.3µl H2O 
End Point PCR was commenced by incubating the samples at 94°C for 3 minutes 30 seconds, 61°C for 
45 seconds then 72°C for 5 minutes 45 seconds for samples containing either of the tdTomato 
primers or 95°C for 3 minutes 30 seconds, 60°C for 30 seconds and 72°C for 5 minutes and 45 
seconds if samples contained the Cre primer.  
 
The PCR products were then separated on a 2% agarose (Invitrogen) gel containing 0.0004% 
PeqGreen (Peqlab) and the DNA products were visualised under a UV light to determine the 
genotype. 
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2.1.4 Sciatic nerve transaction 
Sciatic nerve transection operations were carried out on mice aged 6-8 weeks. The mice were 
anaesthetised using isoflurane. A small longitudinal incision was made inferior to the femur, 1cm 
from the sciatic notch. Blunt dissection was used to expose the sciatic nerve. The sciatic nerve was 
then transacted at this point. The incision was closed using clips and vetergesic analgesia was given. 
The mice were monitored for any adverse effects.  
 
2.1.5 Harvesting the sciatic nerve 
The mice were sacrificed using an appropriate Schedule 1 method of humane killing as outlined in 
the Animals (Scientific Procedures) Act 1986. The mouse was placed in a prone position and the skin 
was disinfected with 70% ethanol. The skin was removed and the dorsal aspect of the mouse 
exposed. The muscles of the posterior thigh were dissected to expose the sciatic nerve. The nerve 
was cut at the sciatic notch proximally and just before the bifurcation of the nerve distally in order to 
obtain a similar length of nerve in all cases. 
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2.1.6 Immunofluorescence 
Sciatic nerves were harvested as described above. The nerves were placed in 4% PFA for 90 minutes. 
Following this the nerves were transferred into 30% sucrose (Sigma-Aldrich) at 4°C overnight.  The 
nerves were then transferred to a 1:1 mix of 30% sucrose and optimal cutting temperature 
compound (OCT) (Thermo Fisher Scientific) for an hour. The nerves were then embedded in OCT and 
placed in liquid nitrogen. The embedded nerves were kept at -80C until being sectioned. The nerves 
were sectioned using a cryostat at a thickness of 10 microns. Slides were thawed at room 
temperature for 20 minutes. Staining using the antibodies detailed in table 5 commenced as per the 
protocol detailed in 2.2.9 beginning with fixation using 4% paraformaldehyde.  
 
2.1.7 In vivo ethynyl-2’-deoxyuridine (EDU) proliferation assay 
EDU was reconstituted in sterile PBS at a concentration of 5mg/ml; 200µl was injected 
intraperitoneally into adult mice. The mice were left for two hours before being sacrificed. The 
nerves were harvested, mounted and sectioned as described in 2.1.6. The sectioned nerves were 
thawed at room temperature for 20 minutes and stained as per the EDU protocol described in the in 
vitro methods section 2.2.10, commencing at fixation using 4% PFA. 
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2.1.8 Digestion of the Sciatic nerve and SC extraction 
The sciatic nerves were harvested as described above and put into hepes (GE Laboratories) buffered 
Hanks’ Balanced Salt Solution (HBSS) (Thermo Fisher Scientific) on ice. The nerves were then 
transferred to a 60mm plate and chopped as finely as possible using a scalpel. Each nerve was 
covered in a digestion mix containing: 
25 µl  0. 3% Trypsin (Glibco) (30mg in 10ml HBSS)  
25 µl  0.6% Type 2 collagenase (Worthington) (64.8mg in 10ml  HBSS) 
2µl 1 % Hyaluronidase (Worthington)     
The nerves were incubated in the digestion mix for 10 minutes at 37°C. The mix was then triturated 
5 times using a 1ml pipette tip before a further 10 minutes at 37°C. Immediately following this 200µl 
of dissociation buffer was added to each sample to stop the digestion reaction and the sample was 
triturated 20 times with a 200µl pipette tip. Each sample was then added to 5ml of dissociation 
buffer and centrifuged at 1000 revolutions per minute (rpm) for 10 minutes at 4°C. The supernatant 
was removed and the cell pellet was resuspended in 350µl of FACS buffer containing RNAsin 
(Promega) (8.75µl per 350µl of FACs buffer). The samples were then sorted using the Aria III machine 
into either RLT buffer for RNA extraction or into dissociation media if the cells were to be plated 
following sorting. 
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2.1.9 SC specific RNA extraction 
RNA was extracted using the RNeasy micro kit (Qiagen). The samples were collected into 350µl of 
buffer RLT containing 3.5µl of beta mercaptoethanol (Sigma-Aldrich).  The samples were then spun 
through a gDNA eliminator column at 10000 rpm for 30 seconds to remove genomic DNA. The flow 
through was mixed with the same volume (350µl) of 70% ethanol. The sample was then transferred 
to an RNeasy spin column and centrifuged for 15 seconds at 8000 rpm. The flow through was 
discarded. Then 70µl of buffer RWI was added to the column and spun at 8000rpm for 15 seconds. 
The flow through was discarded. 500µl of buffer RPE was then added to the spin column and then 
the samples were spun at 8000 rpm for 15 seconds. The flow through was discarded. Next 500µl of 
80% ethanol was then added to the column before a spin at 8000rpm for 2 minutes. The flow 
through was discarded and the RNeasy spin column was transferred to a new collection tube, this 
was then spun, with the lid open for 5 minutes at full speed, to completely dry the membrane. Next 
14µl of RNase free water was added to the spin column and the column spun at 10000 rpm for 1 
minute to elute the RNA. The RNA was then either analysed using the bioanalyser or reverse 
transcribed and used for quantitative PCR (qPCR) in the same way as set out in sections 2.2.5-2.2.6 
below.  
 
2.1.10 Bioanalyzer 
A bioanalyser (Agilent Technologies) was used to assess the quality and quantity of the RNA 
collected using an RNA pico chip (Agilent Technologies). The bioanalyser electrodes were 
decontaminated using nuclease free water. The gel dye mix was prepared by spinning 65µl of RNA 
pico gel mix at 1500 G force (g) for 10 minutes, before adding 1µl of RNA dye concentrate and mixing 
well. The RNA pico chip was then placed in the chip priming station and 9µl of the gel dye mix was 
placed in the well marked ‘G’. A plunger at the 1ml position was placed over this well and pressed 
down to prime the chip. 9µl of gel dye mix was placed in each of the 2 wells marked ‘blank G’ and 
5µl of RNA pico marker was pipetted into all other wells. Then 1µl of RNA pico ladder was pipetted 
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into the well marked ladder. A 1.5µl aliquot of the sample RNA was denatured by heating at 70°C for 
2 minutes, 1µl of this was then transferred to each sample well. The chip was vortexed for 1 minute 
then transferred to the bioanalyser for analysis.  
 
2.1.11 Plating and Staining SC following Sorting 
FAC sorted cells were collected into 350µl of dissociation buffer which was transferred to a PLL 
coated well of a 4 well plate. The collection tube was rinsed with a further 350µl of dissociation 
buffer which was added to the same well. The cells, post sort, could then be visualised using bright 
field and fluorescent microscopy. The cells were maintained in an incubator set at 37°C with 10% 
CO2. After being left overnight to adhere to the plate the cells were then stained with Calcein AM, a 
cell permeable dye which is used to determine cell viability. Calcein AM was added to the media at a 
concentration of 1:10 000 and incubated for 10 minutes before being visualised under a fluorescent 
microscope.  
 
2.1.12 RNA seq library preparation 
The cDNA libraries for the in vivo samples were made by Dr Mel Clements, a senior research fellow. 
cDNA for RNAseq was prepared from total RNA using the smart seq 2 protocol (Picelli et al., 2013). 
For reverse transcription 500pg total RNA was mixed with 1µl of 10µM anchored oligo-dT primer and 
1µl of 10mM dNTP mix. The mixture was denatured at 72°C for 3mins and then immediately placed 
on ice. First strand reaction mix (0.5 µL SuperScript II reverse transcriptase, 0.25µl RNase inhibitor, 
2µl Superscript II first strand buffer, 0.25µl DTT, 2µl betaine, 0.9µl MgCl2, 1µl TSO, 0.1µl RNase free 
water) was made and 7µl of this mix was added to each sample. Reverse transcription was initiated 
by incubating at 42°C for 90 min, followed by 10 cycles of (50°C for 2 minutes, 42°C for 90min).  This 
was inactivated by incubating at 70°C for 15min. After this PCR preamplification of the first stranded 
mix commenced; The PCR master mix was made using  10µl of  first strand mix,  25µl KAPA HiFi 
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Hotstart Ready Mix, 1µl ISPCR primers and 14µl nuclease free water. This was subject to 98°C for 3 
min then 15 cycles of (98°C 15sec, 67°C 20sec, 72°C 6 min) with a final extension at 72°C for 5 
minutes. The PCR mix was purified using 1:1 ratio of AMPure XP beads, with the final elution 
performed in 15µl of EB solution.  Following this the library size was checked using a High sensitivity 
DNA chip (Agilent Technologies) following  a 1:5 dilution (expected average size should be 1.5-2.0kb 
and the fragments below 300bp should be negligible). 
5ng of cDNA was then used for the tagmentation reaction which was carried out with the Nextera XT 
DNA sample preparation kit (Illumina), with the addition of 25µl of 2x Tagment DNA buffer and 5µl 
of Tagment DNA enzyme, in a final volume of 50µl. The tagmentation reaction was incubated at 55°C 
for 5 min. The tagmented DNA was then purified using the DNA Clean & Concentrator kit (Zymo 
Research), with the final elution in 20µl of resuspension buffer from the Nextera XT kit.  
The whole volume was then added to 15µl Nextera PCR primer mix, 5µl of index 1 primers, 5µl of 
Index 2 primers and 5µl of PCR primer cocktail for limited cycle PCR enrichment. A second round of 
amplification was then performed by incubating at 72°C for 3 min then 5 cycles of (98°C 10sec, 63°C 
30sec, 72°C 3min). The DNA was then purified using a 1:1 ratio of AMPure XP beads.  The quality of 
the library was then checked using a high sensitivity DNA chip and the DNA was quantified using 
Qubit High Sensitivity DNA kit (ThermoFisher Scientific).The libraries were then diluted to a final 
concentration of 2nM, the samples were pooled and 10pmol were sequenced using the MiSeq 
sequencer (Illumina). 
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2.2 In Vitro Methods 
2.2.1 Isolation and culture of rat Schwann Cells 
All cell culture work was carried out in a class II microbiological safety cabinet (Nuaire). Primary 
Schwann cells were derived from the sciatic nerves of P7 Sprague-Dawley rats (Mathon et al., 2001).  
Briefly sciatic nerves from 10 p7 rat pups were removed and finely chopped before being placed in a 
digestion mixture of DNase (New England Biolabs), collagenase (Worthington) and trypsin (Gibco, 
Life Technologies) for 35minutes at 37°C, with gentle titration at 15 minutes. The reaction was 
stopped by adding 10% fetal calf serum (Sigma-Aldrich) and the cells were spun at 1300rpm for 6 
minutes. The cells were re-suspended in 0.1% bovine serum albumin (BSA) (Sigma-Aldrich) in L15 
media (Leibovitz) (Sigma-Aldrich). The cells were filtered through a 20µm gauze and plated on an 
Ox42(Harlan sera-lab, MAS 370p) coated plate for 30 minutes at room temperature to remove 
macrophages. The non-adherent cells were then plated on an Ox7 coated plate and incubated for 30 
minutes at room temperature to remove fibroblasts. This was repeated twice and the supernatant 
then spun in 0.5% BSA. The cells were re-suspendered in SC media and plated onto poly-L-lysin (PLL) 
(Sigma-Aldrich) coated dishes. The cells were cultured in a dedicated cell culture incubator in 
maximum humidity at 37°C in 10% CO2. The media was replaced every other day.     
 
Once confluent cells were used for experiments or split between further plates. The cells were split 
by aspirating the SC media off and rinsing the cells twice in phosphate buffered saline (PBS) (Sigma-
Aldrich).  1.5ml of pre-warmed trypsin was added until the cells visibly began to curl from the plate.  
At this point the trypsin was removed and SC media was added to the plate. The media was used to 
rinse the plate to collect as many cells as possible. Cells were quantified using a casy-counter and 
plated onto PLL coated dishes at the appropriate density. The media was replaced the following day 
and every other day until cells were ready to be split again or used for experiments. 
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2.2.2 Dedifferentiation assay 
a) Differentiation assay 
Treatment of rat SC in culture with 1mM dibutyryl cAMP (Sigma-Aldrich) for 3 days has been shown 
to induce differentiation of SC (Morgan et al. 1991). Once SC had grown to confluence, they were 
rinsed 3 times in serum free defined media (SATO) and transferred to SATO containing 1mM cAMP. 
The cells were collected or went on to the dedifferentiation protocol after 3 days, with fresh 
SATO/cAMP media at day 2. 
 
b) Dedifferentiation assay 
 Following 3 days in cAMP the cells were rinsed three times in SATO to remove the cAMP. They were 
then transferred into, unless otherwise stated, SATO containing 10% charcoal stripped foetal calf 
serum (FCS) and 200ng/ml Recombinant Human Heregulin beta-1 (NRG) (Peprotech) or control 
conditions (SATO alone). The media was replaced every other day. 
 
c) Interrogating the dedifferentiation assay 
In an attempt to unpick the pathways involved in dedifferentiation of the cultured SC following NRG 
and FCS treatment the SC were treated with JNK inhibitor and/or MEK inhibitor. Following 3 days in 
cAMP the cells were rinsed 3 times in SATO to remove the cAMP and transferred to SATO containing 
10% charcoal stripped FCS and 200ng/ml NRG with 30µM of the MEK inhibitor U0126 (Cell 
Signalling) and/or 30mM of the JNK inhibitor SP600125 (Sigma-Aldrich). Cells were collected for 
downstream experiments after 24 or 48 hours of treatment.  
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2.2.3 RNA extraction 
Before RNA extraction the areas and equipment used were cleaned in RNAZap (Thermo Fisher 
Scientific) and all materials used were RNAse free where possible. For RNA extraction cells were 
directly harvested into 400µl Trizol reagent (ThermoFisher Scientific). The samples were then 
incubated at room temperature for 5 minutes to allow nucleoprotein complexes to completely 
dissociate. The samples were then spun at 12 000g for 10 minutes at 4°C after which the 
supernatant was transferred to a fresh tube. 80µl of chloroform was then added to the supernatant 
and the samples vortexed well then incubated at room temperature for 15 minutes before being 
spun at 12000g for 15 minutes at 4°C. This allows the sample to be separated into 3 layers; the 
bottom organic phase containing protein and lipids, the interphase containing DNA and the aqueous 
top phase containing RNA. The top aqueous phase was carefully transferred to a fresh tube, ensuring 
that there was no interphase taken to ensure no DNA contamination of the samples. The aqueous 
phase was then gently mixed with 200µl of isopropanol and incubated for 10 minutes at room 
temperature. This was followed by an 8 minute spin at 12000g at 4°C. After this an RNA pellet was 
visible in the tube. The supernatant was removed without disturbing the pellet and the pellet was 
washed by adding 400µl of 75% ethanol and spinning at 12000g for 5 minutes. The ethanol was then 
completely removed and the pellet was air dried for 4 minutes before being re-suspended in 11µl of 
RNase free water (Gibco Life Sciences). The amount of RNA present was then quantified using a 
nanodrop (Thermo Scientific). 
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2.2.4 DNase Treatment 
To remove any contaminating DNA from the RNA sample the Turbo DNA-free kit (ThermoFisher 
Scientific) was used. A 0.1 volume of 10x DNase buffer and 0.2µl of rDNaseI was added to each RNA 
sample and gently mixed. The samples were then incubated at 37°C for 20 minutes. 2µl of DNA 
inactivation reagent was added to each sample and the samples were incubated at room 
temperature for 2 minutes. To remove the DNA inactivation reagent the samples were spun at 
10000g for 1.5minutes and the RNA was transferred to a fresh tube on ice.   
 
2.2.5 Reverse Transcription 
The RNA samples were then converted to cDNA using the iScript cDNA synthesis kit (BioRad). For 
each sample 4µl of 5x iScript reaction mix and 1µl of iScript reverse transcriptase were added to the 
RNA and each sample was made up to 20µl with RNase free water. The samples were incubated at 
25°C for 5 minutes, 42°C for 30 minutes and then 85°C for 5 minutes. The cDNA was then diluted 
with 40µl of water to a total volume of 60µl.  
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2.2.6 qPCR 
All qPCR primers were designed using the online tools GenScript (https://www.genscript.com/ssl-
bin/app/primer) and Primer-BLAST (http://www.ncbi.nlm.nih.gov/tools/primer-blast/). For a 
complete list of primer sequences used see tables 3 and 4. 
 For each sample primers were made up as follows; 
10uL MESA Blue PCR Master mix (Eurogenetic) 
8.5uL Water 
0.5uL Primer (10uM) (Sigma-Aldrich) 
1uL  cDNA 
 Samples were repeated in duplicate. The plates were analysed using a BioRad CFX96 Real Time 
system and a cycle over threshold (Ct) value was obtained. The Ct value for each primer was 
compared to the Ct value for a house keeping gene beta 2 microglobulin (B2M) and the fold change 
of each primer was found by comparing the differences of each primer to the control group (delta 
delta Ct-method). 
 
2.2.7 Protein extraction 
Cells were washed twice in ice cold PBS then 50uL of RIPA buffer (Sigma-Aldrich), with 0.1uL of 
phosphatase inhibitors (Sigma-Aldrich) and 0.5uL of protease inhibitor (Sigma-Aldrich), was added to 
the dish. Cells were scrapped into the buffer using a cell scrapper. The cell/buffer mix was 
transferred to an eppendorf tube and left on ice for 10 minutes. The sample was spun at maximum 
speed for 1 minute and the supernatant was transferred to a new tube. The protein content was 
measured against a BSA standard using the Bio-Rad protein assay dye reagent (Bio Rad). 
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2.2.8 Western Blot 
The desired amount of protein lysate was added to 4x laemmli buffer (Bio-Rad) and made up to a 
50µl volume with water. The samples were then boiled at 95°C for 10 minutes to denature the 
proteins. The samples were run on polyacrylamide gels and resolved by sodium dodecyl sulphate-
polyacrylamide gel electrophoresis (SDS-PAGE) to separate out the proteins. The gel was transferred 
to a polyvinylidene difluoride (PVDF) membrane. The membrane was blocked in 5% milk (Sigma-
Aldrich) in Tris-Buffered Saline with 0.05% Tween 20 (Prolabo) (TBS-T) for an hour at room 
temperature. The membranes were then transferred to the primary antibody diluted to the 
appropriate concentration (see table 2) in 5% milk TBS-T overnight at 4°C. The membranes were 
then washed three times in TBS-T before being transferred to the appropriate HRP-conjugated 
secondary antibody (see table 2) diluted in 5% milk TBS-T and incubated at room temperature for an 
hour. After 2 washes in TBS-T the membranes were transferred to TBS and 
electrochemiluminescence (ECL) was detected using ECL Luminata Crescendo reagent (Millipore).   
 
2.2.9 Immunofluorescence 
After treatment with cAMP, NRG or control media the media was removed from the SC and the cells 
were fixed in 4% PFA at room temperature for 20 minutes. The cells were then washed twice in PBS 
before being permeabilised in 0.5% Triton X-100 in PBS for 15 minutes at room temperature, SC 
were then washed twice in PBS and then transferred to 3% BSA in PBS for blocking. The cover slips 
were then incubated in the stated primary antibodies at the concentrations highlighted in table 2, 
diluted in 3% BSA, overnight at 4°C. The next day the cover slips were washed 3 times in PBS and 
transferred to the relevant secondary antibody diluted in 3% BSA (see table 2) for an hour at room 
temperature. The cover slips were then washed twice in PBS and once in water before being 
mounted. Fluorescence was visualised using epifluoresence, images were captured using Leica 
software and images were processed using ImageJ.   
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2.2.10  EDU proliferation assay 
The proliferation rate of the cells was measured after treatment with cAMP, NRG or control media 
using the Click-iT EdU assay (Invitrogen). EDU is a thymidine analogue which is incorporated into the 
DNA during cell division. The EDU is detected by a ‘click’ reaction; a covalent reaction between an 
azide (the Alexa Fluor dye) and an alkyne (the EDU) which is catalysed by copper.  
Rat SC were plated on glass cover slips which had been PLL and laminin (Sigma-Aldrich) coated at a 
density of 80 000 cells per well. The SC were subject to the conditions described in the 
differentiation and dedifferentiation assays. EDU solution was added to the media of the cells for a 
final EDU concentration of 10uM, the cells were incubated with the EDU for 4 hours. After this time 
the media was removed and the SC were fixed at room temperature for 15 minutes using 1ml of 4% 
paraformaldehyde (PFA) (TAAB Laboratories Equipment) in each well containing SC. The PFA was 
removed and the cells were washed twice with 1ml 3% BSA in PBS. The cells were then 
permeabilised in 0.5% Triton X-100 (Sigma-Aldrich) in PBS at room temperature for 20 minutes. The 
Click-iT reaction cocktail was prepared; per cover slip 43µl of 1xClickiT reaction buffer, 2µl copper 
sulphate (CuSO4), 0.12µl Alexa Fluor azide and 5µl reaction buffer additive. The cells were washed 
twice in 1ml of 3% BSA in PBS. The cells were then incubated in 50µl of the Click iT reaction cocktail 
for 30 minutes at room temperature. The cells were then washed once in 3% BSA in PBS and once in 
PBS alone. The nuclei of the cells were then stained with 4’,6-Diamidino-2-Phenylindole, 
Dihydrochloride (DAPI) (Insight Technology) at 1 in 5000 in PBS for 5 minutes at room temperature. 
The SC were then washed twice in PBS and mounted. The SC were visualised under a fluorescent 
microscope. 
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2.1.11 RNAseq library preparation 
The cDNA libraries for the in vitro samples were prepared by Miss Katrin Goetsch, a research 
assistant. cDNA libraries for RNA seq analysis were prepared using the NEBNext Ultra Directional 
RNA Library Prep Kit for Illumina (New England Biolabs). RNA was prepared from 4 cAMP treated 
(differentiated) samples and 4 NRG and FCS treated (dedifferentiated) samples and treated with 
DNase to remove contaminating genomic DNA as detailed in 2.1.3 and 2.1.4. The RNA was quantified 
using a nanodrop and 500ng of total RNA was used to make libraries. The first strand synthesis 
reaction buffer and random primer mix was prepared by mixing 8µl NEBNext First Strand Synthesis 
Reaction Buffer (5x), 2µl NEBNext random primers and 10µl nuclease free water. The total RNA was 
diluted with nuclease free water to a volume of 50µl. Then 20µl of NEBNext oligo d(T)25 beads were 
transferred to a 0.2ml PCR tube. The beads were washed twice by adding 100µl of RNA binding 
buffer (2x) to the beads and mixing, then transferring the tube to a magnetic rack at room 
temperature for 2 minutes before removing the supernatant. Following this the beads were re-
suspended in 50µl of RNA binding buffer (2x) and the 50µl of total RNA was also added to the tube. 
The tube was then placed on the thermal cycler and the sample was heated at 65°C for 5 minutes 
then kept at 4°C to denature the RNA and help the poly-A mRNA bind to the beads. The samples 
were then mixed and incubated at room temperature for 5 minutes to allow the mRNA to bind to 
the beads. The tube was then placed on a magnetic rack at room temperature for 2 minutes to 
separate the poly-A mRNA bound to the beads from the solution. The supernatant was discarded 
then the tube was removed from the magnetic rack. The beads were washed twice by adding 200µl 
of wash buffer and mixing. The tube was placed on the magnetic rack for 2 minutes at room 
temperature before the supernatant was discarded. 50uL of Tris buffer was added to each tube and 
mixed. The tube was then placed on the thermal cycler and the samples heated at 80°C for 2 
minutes and then held at 2°5C to elute the Poly-A mRNA from the beads. After this 50µl of RNA 
binding buffer (2x) was added to the sample to allow the mRNA to re-bind to the beads, this was 
incubated at room temperature for 5 minutes. The tube was then placed on the magnetic rack for 2 
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minutes and the supernatant removed. The beads were then washed with 200µl of wash buffer and 
placed back onto the magnetic rack for 2 minutes before removing all of the supernatant. The mRNA 
was eluted from the beads by adding 15.5µl of the First Strand Synthesis Reaction Buffer and 
Random Primer Mix (x2) and incubating the samples at 94°C for 15 minutes before immediately 
placing the tubes on the magnetic rack. The purified mRNA was collected by transferring 13.5µl of 
the supernatant to a fresh tube on ice. First strand DNA synthesis was performed by adding 0.5µl of 
murine RNase inhibitor, 5µl actinomycin D (0.1µg/µl) (Sigma-Aldrich) and 1µL ProtoScript II reverse 
transcriptase to the fragmented and primed mRNA and this was incubated in a thermal cycler with 
heated lid set at 105°C for 10 minutes at 25°C, 15 minutes at 42°C and 15minutes at 70°C before 
being held at 4°C. Second strand cDNA synthesis was then performed by the addition of 48µl of 
nuclease free water, 8µl of Second Strand Synthesis Reaction Buffer (10x) and 4µl of Second Strand 
Synthesis Enzyme Mix to the samples. This was gently mixed and incubated on the thermal cycler for 
1 hour at 16°C with the heated lid set at 40°C. The double stranded cDNA was then purified by the 
addition of 144µl of AMPure XP beads to the sample which was vortexed and incubated at room 
temperature for 5 minutes. The sample was briefly spun and then placed on a magnetic rack for 5 
minutes, until the solution was clear. The supernatant was then discarded. The samples were 
washed twice in 200µl of fresh 80% ethanol. The beads were then air dried for 5 minutes before the 
DNA was eluted from the beads into 60µl of 10mM Tris-HCl with a 2 minute incubation at room 
temperature. The tube was then placed on the magnetic rack and 55.5µl of the supernatant was 
then removed to a fresh PCR tube. 6.5µl of NEBNext End Repair Reaction Buffer (10x) and 3µl of 
NEBNext End Prep Enzyme Mix was added to the purified double stranded cDNA and the samples 
was incubated on the thermal cycler with the heated lid set at 75°C for 30 minutes at 20°C and 30 
minutes at 65°C before being held at 4°C. Immediately following this adaptor ligation was performed 
by adding 15µl Blunt/TA ligase Master Mix, 1µl of NEBNext Adaptor (diluted 1 in 10 with 10mM 
Tris/HCl, pH 7.5 with 10mM NaCl) and 2.5µl of nuclease free water, mixing and incubating at 20°C for 
15 minutes on the thermal cycler. Nuclease free water was added to the samples to bring the 
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volume to 100µl and 100µl of AMPure XP beads were added to the sample before mixing and 
incubating at room temperature for 5 minutes. The samples were then put on a magnetic rack and 
supernatant was removed before the beads were washed twice with 200µl of 80% ethanol. The 
beads were then air dried before the DNA target was eluted from the beads by adding 52µl of 10mM 
Tris-HCl, incubating at room temperature for 2 minutes and placing on the magnetic then 50µlof the 
supernatant was then transferred to a fresh tube and the beads were discarded. 50 µl of AMPure XP 
beads were added to the sample and the process was repeated. After air drying the DNA target was 
eluted with 19µl of 10mM Tris-HCl and incubated for 2 minutes at room temperature before being 
placed back on the magnetic rack and 17µl of the supernatant was transferred to a fresh tube and 
PCR enrichment was performed by adding 3µl NEBNext USER Enzyme, 25µl NEBNext Q5 Hot Start 
HiFi PCR master mix (2x), 2.5µl of universal PCR Primer/i5 Primer and 2.5uL of Index Primer/i7 
Primer. The samples were then incubated on the thermal cycler for 15 minutes at 37°C, 30 seconds 
at 98°C , then 12 cycles of (98°C for 10 seconds and 65°C for 75 seconds) followed by 5 minutes at 
65°C before being held at 4°C. The PCR reaction was then purified by adding 45µl of AMPure XP 
beads, mixing and incubating at room temperature for 5 minutes. The samples were then placed on 
a magnetic rack and the supernatant was then removed. The samples were washed twice in 200µl of 
80% ethanol before being air dried for 5 minutes. The target DNA was then eluted into 23µl of 
10mM Tris and incubated for 2 minutes at room temperature before being placed onto a magnetic 
rack where 20 µl of the supernatant was removed to a fresh PCR tube and an aliquot was used to 
asses library quality on the bioanalyser (Agilent Technologies) using a DNA high sensitivity chip 
(Agilent Technologies). The samples were then sequenced using a Miseq sequencer (Ilumina).                  
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2.3 Media and Solutions 
2.3.1 Nerve dissociation media  
 
Dissociation Media 
19 mls low glucose DMEM (lonza) 
5% Horse Serum (Invitrogen) 
10µl/ml Penicillin/Streptomycin (TermoFisher Scientific) 
__________________________________________________________________________________ 
FACs Buffer 
Sterile PBS 
1mM Ethylenediaminetetraacetic acid (EDTA)(Sigma-Aldrich) 
25mM Hepes (GE laboratories) 
1% FCS 
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2.3.2 Cell culture media 
SC Media 
500ml DMEM (lonza) 
15mls charcoal stripped foetal calf serum 
10mls Glutamine 
1.2 mls Kanamycin/Gentamicin 
600µl Glial Growth Factor 
500µl Forskolin 
__________________________________________________________________________________ 
SATO 
400ml Dulbecco’s modified Eagle’s medium (DMEM) 
100µg/ml BSA 
60ng/ml Progesterone (Sigma-Aldrich)  
16µg/ml Putrescine (Sigma-Aldrich)   
40ng/ml Selenium (Sigma-Aldrich)  
50ng/ml Thyroxine (Sigma-Aldrich) 
50ng/ml Triiodothyrine  (Sigma-Aldrich)  
__________________________________________________________________________________ 
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2.3.3 Western Blot Solutions 
Resolving Gel 4% 6% 8% 10% 12% 
30% Acrylamide 2ml 3ml 4ml 5ml 6ml 
4x Tris-HCl-SDS pH8.8 3.75ml 3.75ml 3.75ml 3.75ml 3.75ml 
APS 100µl 100µl 100µl 100µl 100µl 
TEMED 20µl 20µl 20µl 20µl 20µl 
H2O 9.13 8.13 7.13 6.13 5.13 
 
Stacking Gel  4% 
30% Acrylamide 666µl 
Tris-HCl-SDS pH 6.8 1.25ml 
APS 50µl 
TEMED 10µl 
H2O 3.024ml 
 
Running Buffer (pH8.3) 
1L distilled H2O 
25mM Tris pH9.3 (30.28g) 
192mM Glycine  (144.13g) 
0.1% SDS 
__________________________________________________________________________________
Transfer Buffer (pH8.3)  
800ml of distilled H2O  
25mM Tris pH9.3 (30.28g) 
192mM Glycine  (144.13g) 
20% Methanol 
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2.4 Primers for end point PCR (genotyping) 
Primer 
 
Forward sequence 
(5’ to 3’) 
Reverse sequence 
(5’ to 3’) 
tdTomato wild type AAGGGAGCTGCAGTGGAGT CCGAAAATCTGTGGGAAGTC 
tdTomato mutant GGCATTAAAGCAGCGTATCC CTGTTCCTGTACGGCATGG 
Cre AATGCTTCTGTCCGTTTGCC CTACSCCAGAGACGGAAATC 
 
 
 
2.5 Mouse primers for qPCR 
Primer 
 
Forward sequence 
(5’ to 3’)  
Reverse sequence 
(5’ to 3’) 
P0 CTTTGCCCTACCCCAGCTATG ACGGCACCATAGATTTCCCT 
PMP ACTGTACCACATCCGCCTTG CGCACAGACCAGCAAGGATT 
PLP CACCTGTTTATTGCTGCGTT ATGAAGGTGAGCAGGGAAAC 
MBP ATCCAAGTACCTGGCCACAG TGTGTGAGTCCTTGCCAGAG 
P75NTR AGCTCCCAGCCTGTAGTGAC GCAGCTGTTCCATCTCTTGA 
cJun AGCAGACGCTTGAGTTGAGA GGGTCCCTGCTTTTGAGATAA 
Krox 24 CCATCACCTATACTGGCCGC AAAGGGGTTCAGGCCACAAA 
Sox2 CATGGGCTCTGTGGTCAAGT TACATGGTCCAATTCCCCCG 
N-cadherin ATGCTGACCACTCTCACTGC CCCGTTCACAGGGTCTATTT 
Cyclin D1 GCACAACGCACTTTCTTTCC TCCAGAAGGGCTTCAATCTG 
Cdh5 TGTGGGAAAGATCAAGTCCA TTCCCTGTGTTAGCATCGAC 
Nefl CAAGGACGAGGTGTCGGAAA TGATTGTGTCCTGCATGGCG 
 
 
 
Table 3: Sequences of mouse primers used for qPCR. 
Table 2: sequences of primers used for genotyping 
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2.6 Rat primers for qPCR  
Primer 
 
Forward sequence 
(5’ to 3’) 
Reverse sequence 
(5’ to 3’) 
P0 ATTTATGTGCGGGGAGG TCTTTAGGAGGAGGCGACCA 
PMP GCGGTGCTAGTGTTGCTCTT GATCAGTCCTGTGTCCATTGC 
PLP CACCTGTTTATTGCTGCATT ATGAAGGTGAGCAGGGAAA 
MBP TGACAGACTCCAAGCACACA GGCCTGTCTTTGAAGGTGTT 
Periaxin GAGCGGAGTTGGTGGAGATT GTCCCCTTCCTGCAAACTGA 
P75NTR ATTCTCCGATGTGGTGAGCG CCAGTCTCCTCGTCCTGGTA 
cJun GAAATAGGCGAGCGGCTAC TTTGCAAAAGTTCGCTCCCG 
Krox 24 CCATCACCTATACTGGCCGC AAAGGGGTTCAGGCCACAAA 
Sox2 TAGGGCTGGGAGAAAGAAGA GAAGTGCAATTGGGATGAAA 
N-cadherin ATGCTGACCACTCTCACTGC CCCGTTCACAGGGTCTATTT 
Cyclin D1 GCACAACGCACTTTCTTTCC TCCAGAAGGGCTTCAATCTG 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4: Sequences of rat primers used for qPCR. 
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2.7 Antibodies  
Antibody Company Raised 
in 
Western 
Concentration 
IF 
Concentration 
Secondary Antibody 
S100 Dako Rabbit  1 in 1000 Alexa 488 anti 
Rabbit (Invitrogen) 
p75NTR Cell 
Signalling 
Rabbit  1 in 1000 Alexa 488 anti 
Rabbit (Invitrogen) 
Neurofilament Abcam Chicken  1 in 5000 Alexa 488 Anti 
chicken (Invitrogen) 
N-Cadherin BD 
Biosciences 
Mouse  1 in 400 Alexa 594 Anti 
mouse (Invitrogen) 
GFAP Abcam Rabbit  1 in 500 Alexa 488 Anti 
Rabbit (Invitrogen) 
P0 Sigma-
Aldrich 
Goat 1 in 1000  ECL Anti Goat IgG 
horseradish 
peroxidase linked 
(GE Life Sciences) 
Krox 20 Covance Rabbit 1 in 1000  ECL Anti Goat IgG 
horseradish 
peroxidase linked 
(GE Life Sciences) 
Sox 2 Cell 
Signalling 
Rabbit 1 in 2000  ECL Anti Goat IgG 
horseradish 
peroxidase linked 
(GE Life Sciences) 
Beta Tubulin Sigma-
Aldrich 
Mouse 1 in 5000  ECL Anti Goat IgG 
horseradish 
peroxidase linked 
(GE Life Sciences) 
 
 
 
 
Table 5. Details of the antibodies used for immunofluorescence and western blot. 
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3. Results 
3.1 In vivo results 
We aimed to characterise the transcriptional changes seen in SC, in vivo, following nerve injury over 
time. Current knowledge on the key factors that control SC reprogramming following peripheral 
nerve injury is patchy and fragmented, and we are lacking a global overview of the changes 
occurring in the SC specifically. To fulfil our aim we used a mouse sciatic nerve transection model 
and developed a method of extracting SC specific RNA from the sciatic nerve. Below I describe the 
development and validation of this technique. 
  
3.1.1 Validation of the tdTomato mouse line 
 We generated a P0aCre;tdTomato mouse line (as described in materials and methods) in which SC 
are selectively labelled with a red fluorescent protein (as described in materials and methods). We 
began by determining the recombination efficiency in these animals by staining nerves from the 
tdTomato mice with the SC marker S100 and assessing the percentage of co-labelling by counting 
the number of cells (DAPI positive nuclei) per high power field (x40 magnification) which expressed 
s100 and calculating the percentage of these which also expressed tdTomato. We assessed 3 sciatic 
nerves from 3 different tdTomato mice, 3 high power fields were assessed in each nerve. The 
average number of S100 expressing cells per high power field was 279. The percentage of S100 cells 
also expressing tdTomato  was calculated for each high power field and an average over the three 
high power fields for each nerve was calculated (Figure 5). We found that more than 92% of S100 
positive SC also expressed tdTomato, confirming a high recombination efficiency. tdTomato 
expression was not seen in any other cell type examined. These results confirmed that this mouse 
line would prove an excellent tool for identifying and isolating SC from the nerve.  
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Figure 5. The tdTomato/P0 cre mice have a high recombination efficiency. (a-d) 
Representative immunofluorescence images from (a) sciatic nerve from a TdTomato mouse 
which was also stained with (b) SC marker S100 and (c) the nuclear stain DAPI. (d) is the 
merge of images a-c. Scale bar represents 100µm. (e) Graph showing the percentage of 
S100 cells co-labelled with tdTomato in three nerves from tdTomato mice. The percentage  
of cells co-labelled (y axis) for each nerve represents the average percentage of S100 
expressing cells which also expressed tdTomato in 3 high power fields In nerve 1 868 of 926 
s100 expressing cells expressed tdTomato, in nerve 2 668 of 727 s100 expressing cells 
expressed tdTomato and in nerve 3 792 of 861 s100 expressing cells also expressed 
tdTomato. The error bars represent standard error of the mean (SEM). 
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3.1.2 Methods of SC specific RNA extraction 
Both single cell laser capture microdissection and fluorescence-activated cell sorting (FACS) are 
methods which can be used to isolate cells of interest based on their fluorescent properties. We 
thought that these methods, which exploit the red fluorescent properties of the SC in this tdTomato 
mouse line, may provide a way of isolating SC from the nerve. Below I describe how we began to 
asses these techniques.   
 
a) Single Cell Laser Capture Microdissection 
This method allows selection and collection of single cells from tissue sections using a UVA laser 
focused through a microscope to free the cell which is then transferred to a collection cap. This 
system relies on being able to readily identify the cell type of interest, the SC, under a fluorescent 
microscope. This can be easily done in nerves from the tdTomato mouse, without the need for a 
staining step. The tissue is visualised under a microscope and the cells of interest are drawn round 
free hand on a computer, this informs the machine of where to focus the laser on the slide to cut 
around the cell of interest. This is a very time and labour intensive process.. During the time it takes 
to draw around the cells there is bleaching of the fluorescence (as seen in figure 6 (a)), which makes 
identification of SC more difficult as the process goes on.  
  
 
Figure 6.  LCM is a potential method of extracting SC specific RNA from sciatic nerves of the 
Tdtomato mice. (a and b) Representative images from LCM isolation of SC in tdTomato sciatic 
nerves. The nerves were embedded as (a) cross section and (b) longitudinally. Scale bar represents 
30µm (a) and 75µm (b). Images captured from LCM software. 
a b
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We optimised this method in terms of method of OCT removal, embedding the nerves and the lazer 
enrgy used. The RNA extracted using this method was consistently of poor quality (RNA integrity 
number (RIN)<2), therefore we decided that it would be best to abandon this method and focus on 
the FACS method I will go on to descibe. 
 
 b) Fluorescence-activated cell sorting (FACS) 
FACS is a method by which a mixed population of cells is sorted in to separate groups depending on 
the fluorescent properties of those cells. As the mouse line we are using selectively expresses the 
red fluorescent protein tdTomato in the SC, FACS would allow the SC (the red cells) to be separated 
from the rest of the cells in the nerve. To do this the nerve first needs to be digested to a single cell 
suspension that can pass through the FACS machine. The cells are then sorted by the FACS machine 
and used for further downstream analysis. As initial attempts using this method proved promising 
we decided to concentrate our efforts on optimising it.  I will go onto discuss the optimisation and 
validation of the methods used to obtain good quality SC specific RNA (RIN>7) of sufficient quantity 
to make libraries for RNAseq. 
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3.1.3 Optimisation of FACS method of SC specific RNA isolation 
a) Optimisation of the digestion method 
To obtain a single cell suspension needed for FACS the nerve must first be digested. This is a difficult 
process as the nerve is ensheathed in connective tissue which is not readily digestable. The timing of 
the digestion is also critical; this needed to be as short as possible so that cell death is avoided and 
potential changes to RNA expression caused by the digestion were kept to a minimum.  
We optimised the digestion in terms of enzymes used, concentration of those enzymes, and the 
length of time of the digestion.. We assesed the outcome by plating the cells following digestion and 
visualising the cells 2 hours after plating. We assesed the quality of digestion based on the number 
of single cells compared to the amount of nerve tissue which remained in clumps and assesed  cell 
death based on morphological criteria as outlined in the legend below. The results of this 
optimisation process are detailed in tables 6-8. 
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Legend for tables 6-8: 
Quality of digestion  Cell death  
Poor Mainly clumps of tissue. Very few single cells 
Minimal <25% cells are rounded and small. 
Good Several clumps of tissue with easily identifiable single cells. 
Moderate <50% of cells are rounded and small. 
Excellent One or two clumps of tissue with numerous single cells identified. 
Excessive <75% of cells are rounded and small. 
 
Enzyme mix Quality of digestion Cell death 
Trypsin, DNase and collagenase Poor Minimal 
Trypsin, DNase collagenase and hyaluronidase Good Minimal 
Trypsin, DNase collagenase and pronase Good Moderate 
Trypsin, collagenase, DNase hyaluronidase and pronase Excellent Excessive 
   
 
 
 
 
 
  
Table 6. Digestion using trypsin, DNase, collagenase and hyaluronidase is optimal. The table 
shows the outcome of different cocktails of enzymes on the quality of digestion and cell viability. 
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Enzyme mix Quality of digestion Cell death 
Hyaluronidase 0.08%  (Trypsin o.3%, collagenase 0.6%) Excellent Excessive Hyaluronidase 0.04%  (Trypsin o.3%, collagenase 0.6%) Good Excessive Hyaluronidase 0.02%  (Trypsin o.3%, collagenase 0.6%) Good Minimal Trypsin 0.6% (Collagenase 0.6% Hyaluronidase 0.02%) 
Good Excessive 
Collagenase 1.2% (Trypsin 0.3%, Hyaluronidase 0.02%) Good Excessive  
 
Time Quality of digestion 
10 minutes Poor 
20 minutes Good 
30 minutes Good 
40 minutes Excellent 
 
 
We also assesed the outcome of different methods of tissue homogenistation prior to digestion. The 
results (table 9) show the RNA integrity number (RIN), and quantity of RNA obtained following using 
a TissueRuptor and chopping the nerves using a scalpel to homogenise the tissue prior to digestion. 
The RIN and quantity of RNA were calculated using the Agilent bioanalyser. The RIN is calculated by 
analysing the entire electrophoretic trace from the RNA sample which includes the presence or 
absence of RNA degradation products  Traditionally RNA integrtiry was confirmed by obtaining a 28s 
to 18s peak ratio of 2 but this has been shown to provide a weak correlation with RNA integrity and 
RIN has been shown to be a more reporducible and reliable method of RNA integrity analysis 
(Schroeder et al., 2006). 
Table 7. Digestion using 0.02% hyaluronidase, 0.3% trypsin and 0.6% collagenase is optimal. 
Table shows the outcome of different concentrations of enzymes on the quality of digestion 
and cell viability. 
Table 8. Digestion for 20 minutes is optimal. Table shows the outcome of different lengths 
of time of digestion on the quality of digestion. 
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Homogenisation Conditions RIN Quantity (pg/uL) 
TissueRuptor in enzymes 3.5 14 
TissueRuptor post enzymes 1.7 11 
Chopping + harsh trituration (5 times during and 20 times post digestion) 7.8 134 
Chopping + gentle trituration (10 times post digestion) 7.6 48 
  
 
 
Having completed the above optimisation steps we concluded that 20 minutes digestion in 0.3% 
trypsin, 0.6% collagenase type II and 0.02% hyaluronidase, chopping the nerves finely before 
digestion and harsh tituration once the nerves were in the digestion mix were the optimal conditions 
for good quality digestion with minimal cell death (detailed in materials and methods). 
  
b) FACs conditions 
To ensure that the FACS sorting was not causing a significant reduction in the quality of RNA we 
compared the RIN of RNA from an intact nerve that had been digested and FACs sorted before the 
RNA was extracted to that of an intact nerve that was digested in the same way but RNA was 
extracted directly after digestion so the FACS sorting step was omitted. The bioanalyser plots with 
RIN values are seen in figure 7. 
Table 9. Tissue homogenisation by chopping the nerve and harsh trituration is optimal. The 
table shows the effects of different methods of tissue homogenisation on RNA quality (RIN) 
and RNA quantity 
  
 
Figure 7 shows that the FACS step was not having a significant impact on the quality of RNA (RIN 7.6 
in unsorted cells vs RIN 7.3 in sorted cells)
RNA obtained (940 pg/uL in unsorted cells
would be expected as in the unsorted nerves there is RNA from other cell types found in the intact 
nerve as well SC RNA whereas 
inevitable loss of material associated with FACS
described below. 
a
b
Figure 7.FACS does not reduce the quality of RNA obtained from sciatic nerves. (a and b) 
Representative bioanalyser plots showing RNA quality (RIN) from (a) a nerve digested prior to 
RNA being extracted and (b) SC from a nerve digested and FACS sorted prior to RNA being 
extracted. 
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. However we were seeing a decrease in the quantity of 
 vs 36 pg/uL in sorted cells). This reduction in quantity 
the sorted cells should contain SC RNA only, there is also some 
. To overcome this we decided to pool nerves as 
RIN 7.3 
RIN 7.6 
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c) Optimising the number of nerves needed 
As the yield of RNA achieved after FACS was low we decided to see if this could be improved by 
pooling more than one nerve for each sample.  We looked at the difference in quantities and quality 
(RIN) of RNA obtained when pooling 1, 2 and 3 intact nerves, the results are shown in table 10. 
Number of Intact Nerves RIN Quantitiy of RNA (pg/uL) 
1 7.3 104 
2 7.8 325 
3 7.7 717 
  
 
Table 10 shows that following the change described above, pooling nerves had no detrimental effect 
on the RIN and did increase the yield of RNA. We therfore decided to pool 3 nerves for future 
experiments, as this reliably resulted in good quality RNA of sufficient quantities to make cDNA 
libraries for RNAseq. We considered any sample with a RIN greater than 7 good quality 
(Sigurgeirsson et al., 2014). 
 
 
 
 
Table 10. Pooling the RNA from SC from 3 sciatic nerves improves the yield of RNA obtained without 
compromising the quality. The table shows the RNA quality (RIN) and quantity obtained when 1, 2 
and 3 intact sciatic nerves were harvested, digested and FACS to obtain SC specific RNA. 
 3.1.4 Validating the FACS method of extracting SC specific RNA
 Having optimised the protocol to extract SC specific RNA using
obtaining RNA of a sufficient quantity and quality using this method
that the RNA was indeed SC specific. We used several techiniques to do this as I outline below.
 
a)  Flow cytometry 
We first collected, digested and FACS
tdTomato mice and compared t
very little autofluresence in the t
clear population of tdTomato positive cells could be identified. 
well above where the level of autoflurescence
stopped in order to ensure the
types. We also did not collect any cells with high levels of green autoflourescence as these 
were likely to represent a population o
 
 
b) Inspecting cells after FACS
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Figure 8. A clear group of tdTomato positive cells is demonstrated by FACS in sciatic nerves 
from tdTomato mice (a and b) show fluorescence of cells from the sciatic nerves of WT and 
tdTomato mice. The images are representative FACS plots of digested sciatic nerves from (a) 
wild type and (b) tdTomato  mice highlighting levels of tdTomato (red) and green 
autofluorescence. The lines represent the gates used to collect the tdTomato positive 
fraction 
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In order to know exactly what cells were obtained after sorting we harvested and digested 3 
intact nerves from from tdTomato mice and FACs sorted the tdTomato positive and the 
tdTomato negative cells into dissociation media. The cells were then plated onto a PLL coated 4 
well plate and left for 4 hours to attach. After this time the cells were treated with Calcein AM, a 
live/dead cell indicator which is able to enter live cells where it is converted to green flourescent 
calcein by the action of esterases in the living cell. We then visualised the cells under a 
flourescent microscope (see figure 9) which showed that in the tdTomato positive fraction the 
majority of red cells were staining green, meaning that most of the SC were still viable following 
sorting and there were very few cells staining green which were not also co-stained red, 
meaning that the vast majority of the live cells were tdTomato positive therefore SC, which 
suggests we have minimal contamination in the FACS sorted SC from intact nerves. No red cells 
were seen in the tdTomato negative fraction. Around 200 SC were seen from each digested 
nerve. 
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c) Using qPCR 
We decided to further validate the method by harvesting, digesting and FACs sorting intact 
nerves and collecting the tdTomato positive fraction (the SC) and the tdTomato negative fraction 
(the other cells found in the nerve), RNA was made from these two fractions. We also harvested 
and digested whole intact nerves and made RNA, omiting the sorting step. The RNA from the 
three groups (tdTomato positive, tdTomato negative and whole nerve) was made into cDNA and 
qPCR was performed using markers of mature SC (myelin proteins P0, PLP and PMP22) and 
a b tdTomato Calcein 
c d Bright field Merge 
Figure 9.Viable SC are seen following sciatic nerve digestion and FACS.(a-d) Representative 
images at x40 magnification of cells obtained after FACS showing (a) tdTomato expression, 
(b) calcein AM (live cell indicator) staining, (c) bright field image and (d) merge images of 
a-c. Scale bars represent 50µm..  
 markers to help to detect axonal (Nefl) or endothelial
confirm the SC specific nature of the samples
to the whole nerve (figure 10
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Figure 10. Mature SC markers are enriched in the FACS SC when compared 
and to the tdTomato negative fraction. (a and b) Graphs showing the expression of 
differentiated SC (P0, PLP and PMP22), axonal
sorted SC from intact nerves compared to (a) whole intact nerve
of biological replicates. and (b) the tdTomato negative fraction of FACS sorted nerve (n=1) Error 
bars represent SEM of technical replicates. Each gene was normalised to the house keeping gene 
B2M. 
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 We went on to validate this method further by ensuring the ch
SC following nerve injury are seen when
compared to SC from the distal stump of sciatic nerves 3 days post transection
showed the changes expected; d
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We have used flow cytometry, immunoflurescence and qPCR to validate
population of SC from sciatic nerves in mice and reliably extracting good quality
sufficient quanitiy to use for RNAseq.
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Figure 11. Myelin proteins are downregulated and dedifferentiation markers are upregulated in 
FACS SC following nerve transection when compared to FACS SC from intact nerves. The graph 
shows expression levels of differentiated (P0, PLP, PMP22 and MBP) and ded
Sox2 and cJun) SC markers and a proliferation marker (cyclin D1) in digested and FACs sorted SC 
from intact nerves and the distal end of nerves 3 days post sciatic nerve transaction. n=1. Error 
bars represent the SEM of technical replic
gene B2M.  
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3.1.5 Characterising the timing of the SC response to injury 
The SC response to injury begins within minutes of the injury and can last several months, 
dependent on when and if the axons make contact with the distal targets. Therefore, it stands to 
reason that different sets of genes will be upregulated and downregulated over this period of time 
and when we look at the SC at a certain time point we are just getting a snapshot of that instant and 
missing the bigger picture. We aimed to get a temporal picture of the transciptional changes in SC 
following nerve injury by performining RNAseq on SC from the distal end of the transected nerve at 
various time points. 
 In order to pick the best time points at which to analyse the SC transcriptome we began to 
characterise the timining of the dedifferentiation response. We did this by performing qPCR on 
cDNA made from RNA extracted from SC sorted using FACs from intact nerves and the distal stump 
of sciatic nerves 24hours, 48 hours, 72 hours and 7 days following sciatic nerve transection (figure 
12). We assesed expression of differeantiated SC markers (myelin proteins P0, PMP, PLP and MBP), 
dedifferentated SC markers (p75, sox2, cJun and N-cadherin) and a proliferation marker (cyclin D1). 
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Figure 12. Downregulation of myelin proteins and upregulation of dedifferentiation markers 
at the mRNA level can be seen by 24 hours post nerve transection in FACS SC from the distal 
cut nerve. The graph shows the expression of differentiated (P0, PMP, PLP and MBP), 
dedifferentiated (p75, Sox2, cJun and N
(cyclin D1) in SC from the distal sciatic nerve at the stated time points following nerve 
transection. (n=3) * signifies p<0.05 using a 2 tailed unpaired students t test, comparing 
each time point to the intact sample. Error bars represent SEM of biological replicates. Each 
gene was normalised to the house keeping gene B2M.
* 
Differentiated SC
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EDU injection 2 hours before being sacrificed. The contralateral intact nerves were taken as controls. 
The nerves were sectioned and stained with EDU (prolifferation marker), p75 (a dedifferentiation 
marker) and neurofilament (NF) (an axonal marker). For EDU quantification the number of tdTomato 
positive SC in three fields per high power field for each nerve were counted and the number of these 
SC expressing the green fluorescence indicating EDU incorporation and therefore proliferation were 
counted and a pecentage of SC undergoing proliferation was calculted, the results are shown in 
figure 13a. The average number of cells counted per high power field was 310 and the average 
number of SC analysed per nerve was 808.  
In the intact nerve p75 expression is minimal (figure 13f). Dedifferentiated SC express p75, this can 
be seen in figure 13g. p75 expression was analysed by measuring the total length of the nerve in 
milimeters (mm) and the length of nerve with p75 expression (in mm) and expressing the p75 
expression as a percentage of the total length of the nerve ((length of nerve expressing 
p75(mm)/total length of nerve (mm))x100) this is seen in figure 13b.  
NF expression is uniform and linear in intact nerves (figure 13d), when the axon undergoes 
degeneration following nerve injury the NF staining is disrupted (figure 13e). To quantify this the 
total length of the nerve was measured in mm and the length of nerve where NF staining was 
disrupted was measure in mm and the percentage of the nerve with disrupted NF was calculated 
((legnth of nerve with disrupted NF staining (mm)/total length of nerve (mm))x100), this is seen in 
figure 13 c.  
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Figure 13 shows that SC prolifereation is seen initially at 36hours following transection and the 
number of proliferating SC continue to rise with time (a). The protein expression of p75NTR, a key 
dedifferentiation marker, begins at 36 hours following nerve transection, by 60 hours p75NTR 
expression is seen throughout the examined distal nerve (b). Axonal degeneration, as evidenced by 
disruped NF staining, begins at 24 hours after nerve transection and by 48 hours post sciatic nerve 
transection the entire length of the examined distal nerve showed evidence of axonal degeneration 
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Figure 13:SC proliferation and dedifferentiation, and axonal degeneration are seen by 24-36 
hours following nerve transection. SC dedifferentiation and axonal degeneration is seen 
throughout the nerve by 72 hours. The graphs show (a) percentage of EDU positive SC (b) the 
percentage of the nerve staining with p75NTR and (c) the percentage of the nerve that showed 
axonal degradation as seen by disrupted NF staining in intact sciatic nerves and the distal end of 
sciatic nerves at the stated time points following transection. (n=2). (d-g) are representative 
images at x40 magnification of NF staining in green (d and e) and p75 staining in green (f and g) 
in intact (d and f) and the distal nerve stumps72 hours post transection (e and g) .tdTomato is in 
red and nuclear DAPI staining is in blue. Scale bar represents 100µm. 
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(c).  When analysing these sections we noted that EDU expression, p75 expression and NF disruption 
started at the proximal tip of the distal nerve end and progessed distally along the nerve as time 
went on, which suggests that dedifferentiation begins at the cut end of the distal nerve and 
progresses in a wave like fashion distally along the nerve, by 60-72hours the entire nerve appeared 
to be dedifferentiated.  
Unfortunately, due to time constraints it was not possible to perform RNAseq at multiple time points 
but this data shows that to collect the most infomative data several early time points should be 
analysed up to 3 days; we decided that collection 18, 36, 54 and 72 hour time points should catch 
key changes in the SC transcriptome. We also decided a further later time point at 6 days following 
nerve transection would provide useful information to compare the early time points to a later time 
point where the wound would be more established. 
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3.1.6 RNAseq of intact vs distal nerves 
In order to assess the global transcriptional changes that occur following nerve injury in SC we 
performed RNAseq on cDNA libraries made from the RNA extracted from 3 groups of SC FACS sorted  
from intact nerves and 3 groups of SC FACS sorted from the distal end of a nerve 6 days post 
transection. See appendix A for RIN values of samples used for RNAseq. With the help of our 
colleagues at the MRC bioinformatics facility a list of normalised RNA-seq expression data was 
generated which included the fold change of 10005 known genes (24107 in total) between the intact 
and distal samples, along with the significance of the change (p value). 2347 were found to be 
significantly changed between the intact and distal group (p<0.05), of these 1138 (48.5%) were up 
regulated and 1209 (51.5%) were down regulated in the SC from the distal nerve compared to SC 
from intact nerve. 
 We began to analyse the RNAseq data by looking at expression changes between the distal and 
intact nerve of the key genes we used for qPCR in validating the technique (figure 14). These 
represented mature, differentiated SC markers (P0, PMP22, PLP and MBP) and markers of 
dedifferentiation (p75NTR, Sox2, cJun, N-cadherin) and the proliferation marker cyclin D1. 
 
 
 
 
 
 
 
 
  
 
 
 
Figure 14 shows there is down
markers cJun and N-cadherin, and upregulation of the dedifferen
and the proliferation marker cyclin D1 when comparing the
post transection to SC from intact nerves. These results recapitulate the results seen
sorted from the distal nerve at the 7 day time point in figure 12
Gene set enrichment analysis (GSEA) was performed on t
expressed genes between samples from the SC of the distal end of cut nerves 6 days following 
transection compared to from SC from intact nerves. GSEA compares the data to known groups of 
genes which share common biological functions, location or regulation
involves generating an enrichment score which reflects how well the genes known to
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Figure 14.Following nerve transection there is downregulation of myelin proteins an
upregulation of some dedifferentiation markers and a proliferation marker demonstrated by 
RNAseq. The graph shows the fold change in expression of myelin proteins(P0, PMP22, PLP 
and MBP), dedifferentiated SC markers (p75, Sox2, cJun and N
marker cyclin D1 in SC from the distal stump 6 days post nerve transection when compared to 
SC from intact nerves using RNA seq.
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downregulated in the given functional groups match the levels of expression of genes in the RNAseq 
data. The GSEA calculates 4 key statistics for each of the groups of genes the data is compared to 
(Subramanian et al., 2005) . These are; 
 Enrichment score (ES): this reflects the degree to which genes are overlap at the top or 
bottom of a ranked list of differentially expressed genes. A positive ES indicates enrichment 
of genes that are upregulated and a negative ES indicates enrichment of genes that are 
downregulated. The enrichment plot is a graphical representation of the ES for a gene set 
(Subramanian et al., 2005). 
 Normalised enrichment score (NES): ES are normalised to account for differences in gene set 
size therefore can be used to compare results from different gene sets (Subramanian et al., 
2005). 
 False discovery rate (FDR): is the estimated probability that the NES for a gene set is a false 
positive. In most cases where the results are used to generate protential future research 
targets an FDR cut off of 25% is appropriate (q<0.25) (Subramanian et al., 2005). 
 Nominal P value: is the estimated statistical significance of the ES for each gene set. The p 
value is not adjusted for gene set size and multiple hypotheses testing (unlike FDR) 
(Subramanian et al., 2005).  
 
Using GSEA to compare our RNAseq data to groups of genes regulated by different transcription 
factors showed, when using an false discovery rate (FDR) cut off of q<0.25, that no transcription 
factors were significantly upregulated. However, using a nominal P value cut off of p<0.01, 3 
significantly upregulated transcription factors were identified.  Also 2 significantly down regulated 
transcription factors were identified using a FDR cut off of q<0.25. (Figure 15). 
85  
 
 
 
Figure 16 summarises the results of GSEA, when looking at genes enriched in the SC from the distal 
nerve compared to those from the intact nerve.  
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Figure 15.Down and upregulated transcription factors found by GSEA of RNAseq data when 
comparing SC from the distal nerve to SC from the intact nerve. The bar chart shows the 
normalised enrichment scores of significantly upregulated (p<0.01) and down regulated (FDR 
q<0.25) gene sets of transcription factors. 
Figure 16.Downregulation and upregulation in gene sets identified by GSEA, grouped according 
to function, reflects SC biology. The bar chart shows the average normalised enrichment scores 
of significantly upregulated (FDR<0.25 and p<0.01) and down regulated (FDR<0.25) functional 
groups of genes. The number of individual gene sets involved in each group is indicated in 
brackets. Results are from the GSEA analysis of the normalised RNAseq results when comparing 
the SC from the distal nerve to the intact nerve. 
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Figure 16 shows that in SC from the distal nerve there is downregulation of genes involved in lipid 
synthesis and cell adhesion. This is explained by the fact that the SC turn off the myelination 
programme and aquire migratory properties following nerve injury. There is also downregulation of 
genes involved in extracellular matrix interactions and protein metabolism in SC from the distal 
nerve as compared to SC from the intact nerve. There is upregulation of genes involved in 
transcription and translation, protein metabolism, glycolysis and cell cycle as would be expected in 
these transcriptionally active proliferating SC. Upregulation in the extracellular matrix interaction 
genes is in keeping with the migratory abilities the SC acquire and upregulation in genes associated 
with lipid degradation is in keeping with the myelin clearance function the SC have following nerve 
injury. There is also upregulation of genes involved in the inflammatory resonse in the SC of the 
dsital nerve in keeping with the recruitment of inflammatory cells seen following nerve injury. Also 
upregulated are groups of genes associated with stem cell renewal and neural development. 
In 2005 Le et al profiled sciatic nerves from mice with a hypomorphic Krox20 allele, As krox20 is the 
master transcriptional regulator of myelination, the hypomorphic krox20 allele is essentially driving 
SC dedifferentiaion without nerve injury. Le et al. used microarray technology and found the genes 
differentially expressed between the hypomorphic krox20 nerve and an age matched nerve from a 
WT mouse.. When comparing these differentially expressed genes to our in vivo data there was 
significant enrichment of genes differentially expressed in the hypomorphic krox20 nerve when 
compared to a WT mouse with those expressed in the SC from the distal nerve 6 days following 
transection when compared to SC from intact nerves.  Figure 17 shows the enrichment plot of genes 
upregulated (a) and downregulated (b) in the hypomorphic krox 20 nerves when compared to the 
genes differentially expressed in the SC from the distal nerves as compared to the intact nerve. 
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As krox 20 is known to be down regulated in SC following nerve injury (Warner et al., 1998) these 
striking similarities between our in vivo data and the expression profiles of nerves with SC with 
reduced krox20 function help to confirm that our samples are SC specific and we are reflecting SC 
biology when analysing our results. 
 
 
 
 
Figure 17. SC from the distal nerve show a similar gene expression profile to that of nerves from a 
mouse with a hypomorphic krox 20 allele. Enrichment plots from our GSEA showing the 
enrichment of genes (a) upregulated and (b)downregulated  in nerves of mice with hypomorphic 
krox 20 gene when compared to a WT mouse(Le et al., 2005) and those genes differentially 
expressed in SC from distal nerves when compared to intact nerves.  
a b 
 3.2 In vitro Results 
Our aim was to develop a dedifferentiation
SC following nerve injury, in a cell cul
analyse target genes implicated in the dedifferentiation process. 
Treatment of rat SC in culture with 1mM cyclic adenosine monophosphate (cAMP) for 3 days has 
been shown to induce differentiation of SC (Morgan et al.
introducing a step, following this cAMP induced
Below I describe the development and validation of this assay.
 
3.2.1 Validating the differentiation assay
To ensure that SC were differentiating optimally when treated with cAMP we carried out RNA 
extraction and performed qPCR on SC treated with cAMP in serum free defined media (SATO) for 3, 
5 and 7 days. We looked at expression of markers of differentiated SC
of dedifferentiated SC (p75 and cJun), see 
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Figure 18. cAMP treatment of SC for 3 days is sufficient to induce differentiation. Th
change of expression differentiated and dedifferentiated SC genes after treatment with cAMP for set time 
periods. n=1. Error bars represent SEM of technical repeats. Each gene was normalised to the house 
keeping gene B2M. 
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We found that treatment with cAMP for 3 days was sufficient to induce differentiation, with no 
apparent improvement in differentiation seen in cells treated for 5 and 7 days. This is consistent 
with the literature (Morgan et al., 1991). 
 
3.2.2 Optimising the dedifferentiation SC assay 
It is known that in these cAMP differentiated SC the removal of cAMP alone induces SC to down 
regulate the mature myelin gene expression and increase expression of some dedifferentiated SC 
markers (Monje et al., 2010). My goal was to enhance this dedifferentiation aspect of the assay. To 
begin we treated SC with cAMP in SATO for 3 days. Following removal of cAMP we then attempted 
to induce the SC to dedifferentiate by treatment with varying levels of FCS as following nerve injury 
the blood nerve barrier is breached and the SC come into contact with serum. This was done by 
washing off cAMP then treated the differentiated SC with SATO alone and SATO supplemented with 
3%, 5% and 10% FCS for 3 days. We collected the samples, extracted RNA, reverse transcribed this to 
cDNA and looked at expression of differentiated SC markers (P0, PLP and PMP) and the 
dedifferentiated SC markers (cJun, Krox24 and p75NTR) by qPCR (figure 19).  
 
  
 
 
 
Figure 19 shows that FCS did not seem to reliably impro
markers or the increase the expression of dedifferentiated
with FCS looked healthier and there 
We then decided to investigate the effect of 
different growth factors for 3 days. The growth factors used were chosen from factors shown in the 
literature to prevent myelination (NRG, TGF beta
and cause SC proliferation (NRG
1995; Krasnoselsky et al. 1994), the results are seen in figure 20
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Figure 19. Treatment of SC with FCS following cAMP induced differentiation does not 
enhance the dedifferentiation response when compared to cAMP removal. The graph shows 
the fold change of expression of mature SC markers (P0, PLP and PMP) and dedifferentiated 
SC markers (cJun, krox24 and p75) when cAMP is removed from SC and when SC are treated 
with 3%, 5% or 10% FCS following cAMP induced differentiation (n=2). Error bars represent 
SEM of biological replicates. Each gene was normalised to the house keeping gene B2
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Figure 20 shows that when cultured with growth factors alone, other than PMP being significantly 
down regulated in the NRG treated SC when
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Figure 20. Treatment of SC with NRG, TGF and HGF, alone or in combination, following cAMP 
induced differentiation does not enhance
cAMP removal The graphs show the fold change of expression of differentiated (P0, PLP, PMP 
and MBP) and dedifferentiated(sox2, krox 24 and cJun) SC genes after treatment with (a) NRG 
n=4, (b) TGF n=4, (c) HGF n=2, (d)  NRG and TGF  n=4, (e) NRG and HGF  n=2 and(f)  NRG, TGF 
and HGF  n=2. * signifies p<0.05 using a 2 tailed unpaired students t test when compared to 
cAMP removal. Error bars represent SEM of biological replicates. Each gene was normalised to 
the house keeping gene B2M. 
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no significant improvement in the dedifferentiation response seen with the addition of growth 
factors alone. The cells also looked unhealthy and a lot of cell death was observed. We postulated 
that the addition of 10% FCS may have a synergistic effect when used in combination with the added 
growth factors, improving the dedifferentiation response observed and suspected it may also 
improve cell survival. As significant cell death was seen in the samples treated with HGF we decided 
to omit this from further analysis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
When 10% FCS was used in combination with TGF beta
reduction in MBP, there was no significant improvement in the dedifferentiation response. However, 
these preliminary studies did show promising results when NR
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Figure 21. Treatment of cAMP differentiated SC with NRG and 10% FCS show promising results 
which is not seen with TGF and FCS alone or augmented by the addition of TGF. The graphs 
show the fold change in expression of differentiated (P0, PLP, PMP22 and MBP) and 
dedifferentiated (Sox2, krox24 and cJun) SC markers when treated with (a) NRG and 10% FCS  
n=1, (b) TGF and 10% FCS  n=4 and (c) NRG, TGF and 10% FCS  n=2. * signifies p <0.05 using a 2 
tailed unpaired students t test comparing to cAMP removal Error bars represent SEM of 
technical replicates (a) and biological replicates (b and c). Each gene was normalised to the
house keeping gene B2M. 
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serum (figure 21 a); there was down regulation of the differentiated SC genes tested and up 
regulation of the dedifferentiated SC marker genes to a greater extent than that seen with cAMP 
removal alone. These effects on the repair genes seemed to be lost when TGF was added to the NRG 
and 10% serum (figure 21 c). We therefore decided to further characterise the changes seen when 
cAMP differentiated cells were treated with NRG with 10% FCS as outlined below. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 3.2.3 Characterising the dedifferentiation
We went on to characterise this dedifferentiation
differentiated and dedifferentiated
10% FCS after cAMP induced differentiation of the cells caused a reproducible and reliable 
downregulation of differentiated SC
associated with a dedifferentiation
level (figure 22). 
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Figure 22. Treatment of cAMP differentiated SC with NRG and 10% FCS enhances the 
dedifferentiation response at the mRNA level. The graph shows relative expression levels of 
differentiated (P0, PMP, MBP and periaxin) and
cadherin) SC markers in cells treated with NRG and 10% FCS. n=4. * signifies p<0.05 using a 2 
tailed unpaired students t test comparing each treatment group to cAMP. Error bars represent 
SEM of biological replicates. Each gene was normalised to the house keeping gene B2M.
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This was also seen at the protein level, with a reduction in the protein concentrations of krox 20 and 
P0 (compared to cAMP removal) and an increase in the protein levels of sox 2 (as compared to 
cAMP) seen by western blot (figure 23), and by an increase in expression of the dedifferentiation 
markers  GFAP and N Cadherin seen by immunofluorescence (figure 24) in the cells treated with NRG 
and 10% FCS as compared to those treated with cAMP. 
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Figure 23. Treatment of cAMP differentiated SC with NRG and 10% FCS causes reduced protein 
expression of the myelin transcription factor krox20, and the myelin protein P0, and increased 
expression of the dedifferentiation transcription factor Sox2. This is a representative western blot 
showing protein expression of mature SC (krox 20 and P0) and dedifferentiated SC (Sox2) markers. 
A loading control (beta tubulin) was used.  
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Following nerve injury SC regain proliferative properties
FCS also had this characteristic feature we performed
cAMP, cells where the cAMP had been removed and
FCS after cAMP removal and SC growing in the normal SC media
2 cover slips per condition, each with 80,000 SC seeded on them. 100 SC (DAPI positive nuclei) from 
10 different fields over the 2 cover
that were EDU positive was also recor
per condition). The experiment was repeated 3 times  The results show
Figure 24.Treatment of cAMP differentiated SC with NRG and 10% FCS induces increased 
protein expression of dedifferentiation mar
images at x40 magnification of cells treated with (a) cAMP (b)  cAMP then SATO  and  (c) cAMP  
then NRG and 10% FCS and stained with GFAP (green), N cadherin (red) and DAPI (blue). Scale 
bar represents 50µm. 
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These results show that  treatment of SC that have undergone cAMP induced differen
NRG and 10% FCS induces the SC to 
dedifferentiation genes (as seen at mRNA and protein levels) and proliferate, as is seen in SC 
following nerve injury in vivo. 
 
Figure 25. Treatment of cAMP differentiated SC with NRG and 10% FCS causes the SC to regain 
proliferative abilities. (a-c) Representative images at x20 magnification
after being cultured in (a) standard SC media, (b) cAMP  and (c) cAMP for 3 days then NRG with 
10% FCS for 3 days EDU is red and nuclear stain in DAPI blue. Scale bar represents 30µm (d) 
quantifies the percentage of EDU positive 
were analysed for each condition. n=3. *indicates p<0.05  using a 2 tailed unpaired students t 
test when compared to cAMP. Error bars represent SEM of biological replicates
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3.2.4 Interrogating the in vitro dedifferentiation response 
In order to get a better understanding of the pathways involved in the dedifferentiation response 
seen when the cells are treated with NRG and 10% serum, and to begin to understand how well 
these overlap with the pathways involved with dedifferentiation in vivo we tested the effect of 
inhibitors of MEK and JNK pathways on the dedifferentiation response.  
MEK is upstream of ERK, which is thought to be a key signalling pathway involved in SC 
reprogramming after injury (Harrisingh et al., 2004; Napoli et al., 2012) and NRG1 is known to inhibit 
myelination in a MEK dependent manor (Syed et al., 2010). Although we found that the addition of 
the MEK inhibitor to the NRG 10% FCS media in the dedifferentiation SC assay did not prevent the 
down regulation of mature SC genes (P0, PMP, MBP and periaxin) or up regulation  genes associated 
with SC dedifferentiation (p75, sox2 and cJun) as seen in figure 26. This indicates that NRG does not 
act via the MEK pathway in our in vitro system.  
It is known that the increase in expression of cJun in vivo (Blom et al., 2014) and in vitro when cAMP 
is removed from SC in culture (Monje et al., 2010) is via JNK activation. Monje et al., also showed 
that inhibiting JNK did not prevent krox 20 from being lost when cAMP was removed from SC (Monje 
et al., 2010). Our data supports this as adding a JNK inhibitor to the NRG FCS media for 48 hours 
prevented the increased expression of dedifferentiated SC markers (p75, sox2 and cJun) but did not 
stop the differentiated SC genes (P0, PMP, MBP and periaxin) from being downregulated, as seen in 
figure 26. 
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Figure 26. Inhibiting the MEK and JNK pathways in the NRG and FCS treated SC did not 
completely inhibit the dedifferentiation response The graphs show t
differentiated (P0, PMP22, MBP and periaxin) and dedifferentiated (p75, Sox2 and cJun) SC 
markers following treatment with cAMP, NRG and 10% FCS with MEK inhibitor (n=2), JNK 
inhibitor (n=4) and both MEK and JNK inhibitors (n=2) f
signifies p<0.05 using a 2 tailed unpaired students t test compared to the NRG FCS treated SC 
without inhibitors. Error bars represent SEM of biological replicates. Each gene was normalised 
to the house keeping gene B2M.
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Figure 26 shows that the dedifferentiation response induced in SC by NRG with 10% FCS cannot be 
completely inhibited by either JNK inhibition, MEK inhibition or a combination of the two. Although 
the genes associated with a progenitor state are significantly inhibited with JNK inhibition the myelin 
genes are suppressed to similar levels in all conditions. This suggests that multiple signalling 
pathways regulate the repair response seen with the addition of NRG and 10% FCS to SC in culture 
and further work is necessary to unpick the pathways involved.  
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3.2.5 RNA seq of in vitro samples 
In order to assess the global transcriptional changes that occur in the differentiated cAMP treated 
cells and the dedifferentiated NRG and FCS treated cells we performed RNAseq on cDNA libraries 
made from the RNA extracted from 4 different 10cm plates of SC treated with cAMP (differentiated) 
and 4 different 10cm plates of SC treated with cAMP then NRG and 10% FCS (dedifferentiated). Each 
10cm plate contained approximately 800,000 SC. With the help of our colleagues at the MRC 
bioinformatics facility a list of normalised RNAseq expression data was generated which included the 
fold change of 10124 known genes between the differentiated and dedifferentiated samples, along 
with the significance of the change (p value). 6121 were found to be significantly changed between 
the differentiated and dedifferentiated group (p<0.05), of these 3565 (59.7%) were up regulated and 
2556 (40.3%) were downregulated in the dedifferentiated SC compared to the differentiated SC.    
We began to analyse the RNAseq data by looking at expression changes, between the 
dedifferentiated and differentiated in vitro SC, of the key genes we used for qPCR in validating the 
assay (figure 27). We looked at expression of the mature, differentiated SC markers (P0, PMP22, 
periaxin and MBP) and of differentiated SC markers (p75, Sox 2, cJun and N-cadherin). 
 
 
 
 
 
 
 
 
  
 
 
 
Figure 27 shows that there is down regulation of the differentiated SC genes and up regulation of 
the dedifferentiated SC genes seen when in the in vitro
This recapitulates the changes seen when qPCR was used
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Figure 27.Treatment of cAMP differentiated SC with NRG and 10% FCS causes downregulation of 
myelin protein genes and upregulation of dedifferentiation genes as seen by RNAseq The graph 
shows the fold change of differentia
Sox2, cJun and N-cadherin) in the dedifferentiated SC group (NRG/FCS treated) when compared to 
the differentiated (cAMP treated) SC group using RNAseq.
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 3.3 Comparing in vitro dedifferentiation
To begin to understand how the in vitro assay
peripheral nerve injury  in vivo,
vivo models.  
We began by looking at the expression of functional groups of genes expressed in the SC from the 
distal nerve (in vivo) and how these overlapped wit
culture (figure 28a) and the same with
SC in culture (figure 28b). 
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Figure 28 .The in vitro SC dedifferentiation assay shares some common features with our in 
vivo data. This shows an intersection of functional groups of genes upregulated in (a)SC from 
the distal nerve in vivo (green set)  and dedifferentiated SC in vitro (yellow set)  and (b) 
from the intact nerve in vivo (green set) and differentiated SC in vitro (yellow set). The 
numbers in brackets are the numbers of functional groups in each set.
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Figure 28 shows that there were 21 different functional groups of genes with increased expression in 
the SC of the distal nerve when compared to SC from the intact nerve and that there was 
upregulation of  13 different functional groups of genes in the dedifferentiated SC when compared 
to differentiated SC. Of these 10 groups were upregulated in both the SC from the distal nerve and 
the deddifferentiated SC. There was upregulation of 10 different functional groups of genes in the SC 
of the intact nerve when compared to SC from the distal nerve and 11 groups upregulated in the 
differentiated SC. Of these 3 groups were upregulated in both the SC from the intact nerve and 
differentiated SC. 
The GSEA showed that there was enrichment of genes downregulated in nerves from mice with a 
hypomorphic krox20 nerve when compared to nerve from a WT mouse (Le et al., 2005) seen in the 
differentiated SC in vitro (figure 29). 
  
 
 
Figure 29.There is enrichment of genes downregulated in the hypomorphic krox 20 nerves in cAMP 
treated, differentiated SC in vitro The figure shows an enrichment plot from our GSEA showing the 
enrichment of genes down regulated in nerves from mice with hypomorphic  krox20 allele  when 
compared to nerves from WT mice (Le et al., 2005) with those in the differentiated SC in culture when 
compared to dedifferentiated SC in vitro. 
 This significant enrichment of genes downregulated 
expressed in differentiated SC in vit
to the intact (figure 17b). However there was not 
nerve from the hypomorphic krox20 nerve with those upregulated in the dedifferentiated SC
vitro, as was seen in vivo (figure 17
upregulated (a) and downregulated (b) in the nerves from the hypomorphic kr
up and downregulated in our in vivo and in vitro models.
 
 
Figure 30 shows that of the 87 genes that were upregulated in nerves from the hypomorphic krox20 
mouse when compared to nerves from WT mice, 44 (50.6
the distal nerve when compared to SC from the intact nerve and 18 (20
the differentiated SC when compared to the dedifferentiated SC. Of these 7 genes were upregulated 
in all 3 conditions. Of the 87 genes downregulated in
when compared to nerves from WT m
nerve when compared to SC from the intact nerve and 48 (55.2%) were also upregulated in the 
a 
Figure 30. Some genes up and downregulated in the hypomorphic krox20 nerves are also 
differentially expressed in SC from the distal nerve i
Intersection of genes (a) upregulated and (b) down regulated in the nerves of hypomorphic krox20 
mice (red set) with those (a) up  and (b) down regulated in the SC from the
and the dedifferentiated SC (yellow set) when compared to the intact nerve and differentiated SC.
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an enrichment of the genes upregulated in the 
a). Figure 30 compares the number of
ox20 mouse to those 
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ice, 57 (65.5%) were also upregualted in the SC from the distal 
b 
n vivo and dedifferentiated SC in vitro. 
 distal nerve (green set) 
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 individual genes 
 
    
 
 differentiated SC when compared to the dedifferentiated SC. Of these 33 genes were upregulated in 
all 3 conditions. 
We also compared our RNAseq data to genes found to be differentially expressed in
nerves when compared to intect nerves
 
Figure 31 shows that of the 84 g
crush injury (Bosse et al., 2006) 37 (44
nerve and 36 (42.9%) were also up regulated in the dedifferentiated SC. Of these 2
differentially expressed in all 3 conditions.
Appendix B is a list of the genes differentially regulated in hypomorphic krox20 nerves (Le et al., 
2005) which are also differentially expressed in our in vivo SC from distal nerves post transecti
when compared to SC from intact nerves and our in vitro NRG/FCS, dedifferentiated SC when 
compared to cAMP treated differentiated SC.
in crushed rat nerves (Bosse et al., 2006) which are also di
Figure 31. Some genes differentially expressed after crush injury in rat sciatic nerves are also 
differentially expressed in SC from the distal nerve in vivo and in dedifferentiated SC in vitro. 
Intersection of genes differentially expressed in crush injured nerves when compared to intact 
nerves (Bosse et al.) (red set) to those in the SC of distal nerve compared to SC of
vivo (green set) and dedifferentiated SC compared to differentiated SC in vitro (yellow set).
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from distal nerves post transection when compared to SC from intact nerves and our in vitro 
NRG/FCS, dedifferentiated SC when compared to cAMP treated differentiated SC. Appendix D is a list 
of the genes differentially regulated in both the hypomorphic krox20 nerves (Le et al., 2005) and the 
crush injured rat nerves (Bosse et al., 2006) which are also differentially expressed in our in vivo SC 
from distal nerves post transection when compared to SC from intact nerves and our in vitro 
NRG/FCS, dedifferentiated SC when compared to cAMP treated differentiated SC. 
These results show that the in vitro dedifferentiation assay shares some genetic features with its in 
vivo counterpart, this was seen when comparing in vitro data to pulished literature (Le et al., 2005; 
Bosse et al., 2006) and to our own in vivo data.  This provides evidence that this dedifferentiation 
assay would provide a useful screening tool for validating potential key genes implicated in the 
dedifferentitation response in the future. 
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4.  Discussion 
4.1  SC reprogramming in vivo 
 
Although there have been significant advances in our understanding of the molecular mechanisms 
that underlie peripheral nerve repair over recent years, our knowledge is still patchy and we are 
lacking a global understanding of the changes that occur and the factors that control these.  
 
Of the nine papers which use global profiling techniques to compare injured to intact nerves seven 
use microarray technology (Arthur Farraj et al., 2012; Barrette et al., 2010; Bosse et al., 2006; 
D’Antonio et al., 2006; Kubo et al., 2002; Nagarajan et al., 2002; Bosse et al., 2001) which has the 
disadvantage of needing transcript specific probes so cannot detect novel transcripts and is also less 
sensitive and specific at detecting differential expression of genes than RNAseq. Only two recent 
papers (Han et al., 2016, Yi et al., 2015) used RNAseq technology to profile transcriptional changes 
between intact and injured nerves. In six of these papers (Han et al., 2016; Yi et al., 2015; Barrette et 
al., 2010; Bosse et al., 2006;Nagarajan et al., 2002; Bosse et al., 2001)  a crush method of injuring the 
sciatic nerve (as opposed to transection) was used; after crush injury the basal membrane of the 
nerve is still intact therefore peripheral nerve regeneration is facilitated. In all nine of these papers 
(Han et al., 2016; Yi et al., 2015; Arthur Farraj et al., 2012; Barrette et al., 2010; Bosse et al., 2006; 
D’Antonio et al., 2006; Kubo et al., 2002; Nagarajan et al., 2002; Bosse et al., 2001) the whole nerve 
was used meaning the transcriptional changes seen could be due to changes in SC, axons, fibroblasts 
or inflammatory cells. Our work is novel in the fact that it isolates SC from the nerve to look for SC 
specific transcriptional changes following nerve injury. It also uses a transection model of sciatic 
nerve injury, as opposed to crush. This makes our work more clinically relevant as medical 
intervention is more likely to be needed following a transection injury than a crush injury. 
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Our aim was to get a global picture of the transcriptional changes that occur in SC following nerve 
injury. To do this we developed a method of isolating SC specific RNA from sciatic nerves using FACS, 
the RNA we collected was of sufficient quantity and quality to perform RNAseq. One drawback of the 
method was the apparent loss of material caused by sorting (36pg/µL of RNA was obtained from one 
FAC sorted intact sciatic nerve compared to 940pg/µL from an intact nerve when only the FACS step 
was omitted). We overcame this issue by pooling nerves so that we had sufficient quantities of RNA 
to make cDNA libraries from. We also used a method of library preparation that was designed for 
very small quantities of input RNA (Picelli et al., 2013).    
 
RNAseq was performed on SC specific RNA extracted from nerves distal to the injury site at 6 days 
post sciatic nerve transaction and intact nerves. The normalised RNAseq data gave results for a total 
of 10005 known genes and significant changes between the distal and intact groups were seen in 
2347 known genes (p<0.05). 
 
When comparing the results of the RNAseq data (figure 14) to the qPCR data from FACS sorted SC 
from the distal nerve at set time points following nerve transection (figure 12), the RNAseq data 
recapitulated the changes seen at 7 days by qPCR. It may seem surprising that at this time point 
cJun, a transcription factor known to be a key player in SC repair response (Arthur-Farraj et al., 
2012), appeared to be down regulated. This is also the case for N-cadherin, which was also shown to 
be downregulated in SC from the distal nerve in our RNAseq data (figure 14) and also by qPCR at 7 
days (figure 12).  However when GSEA was performed on the RNAseq data cJun was identified as an 
up regulated transcription factor (p<0.05), meaning that genes known to be targets of c-Jun 
overlapped with genes up regulated in the SC of the distal nerve 6 days following nerve injury.  This 
suggests it would be beneficial to perform RNAseq at earlier time points to get a temporal picture of 
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the transcriptional changes in SC following nerve injury. Collection of samples at the 6 day time point 
may be too late to catch changes in transcription factors which may happen initially and then be 
switched off at later stages. The fact that our RNAseq data could identify no significantly up 
regulated transcription factors using FDR <0.25 cut off, supports this. 
The genes which were found to be up-regulated in the SC from the distal nerve 6 days following 
transaction in vivo (figure 16)  were genes known to play roles in functions that SC are known to 
acquire following nerve injury; an enrichment of genes associated with transcription and translation, 
protein metabolism, glycolysis and the cell cycle was seen in keeping with the proliferative 
properties the SC regain, also genes associated with inflammation and extracellular matrix were 
found to be up regulated which is in keeping with the role the SC have in recruiting inflammatory 
cells to the wound site and the migratory abilities the SC acquire following nerve injury. Genes 
associated with lipid degradation were also shown to be up regulated in the SC of the distal nerve, 
this would fit with the myelin breakdown function the SC serve following nerve injury. There was 
also a down regulation in genes involved in lipid synthesis in the SC from the distal nerve when 
compared to SC from the intact nerve in vivo, this fits with the switching off of the myelination 
programme which occurs in SC following nerve injury. The enrichment of genes which play roles in 
these key functions in SC of the distal nerve following injury reflect known SC biology and reassure 
us that the samples we have analysed are SC specific.  
 
The GSEA analysis of the RNAseq data showed that genes found to be up in the nerves from a mouse 
with reduced function of Krox 20 when compared to nerves from WT mice (Le et al., 2005) were 
enriched in the SC from the distal nerve in vivo (figure 17a) and genes down regulated in the 
hypomorphic krox 20 mouse were enriched in SC from the intact nerve in vivo (see figure 17b). Krox 
20 has been reported to be the ‘master regulator of myelin transcription’; it is known to be essential 
for the myelination of SC during development (Nagarajan et al., 2001; Topilko et al., 1994), and is 
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downregulated following nerve injury (Warner et al., 1998). Krox 20 has been reported to have a 
cross-inhibitory relationship with cJun, which is thought to be mediated via JNK signalling (Shin et al., 
2013). This striking overlap of genes from our RNAseq data with those from the nerves from the 
hypomorphic krox 20 mouse helps to confirm the SC specific nature of our samples and further 
reassures us that the changes we are seeing in the in vivo samples do reflect SC biology. 
 
In analysing the RNAseq GSEA results we came across several areas which might prove interesting 
for future analysis; 
 Myc Transcription Factor 
Genes regulated by the expression of the transcription factor Myc were found to significantly 
overlap with genes differentially expressed in the distal nerve compared to the intact nerve 
(p<0.01). Myc target genes and the genes involved in the Myc activation pathway were also 
found to highly significantly correlate with the genes differentially expressed in the distal nerve 
compared to the intact (FDR<0.01).  Myc is a transcription factor which plays a role in cell 
proliferation, apoptosis and cell transformation. In humans, Myc is thought to control the 
expression of around 15% of all genes (Patel et al., 2004). N-myc downstream regulated gene 1 
(NDRG1), which is known to be repressed by myc during mouse development (Shimono et al., 
1999) is known to be highly expressed in mature SC and lost in SC following nerve injury at the 
late stages of myelin breakdown, with protein expression of the gene seen again at the 
remyelinating stage (Hirata et al., 2004). In 2004 Berger et al. showed that loss of this NDRG1 
gene led to a demyelinating neuropathy (Berger et al., 2004).  The highly significant overlap of 
these genes which change in the SC following injury with genes regulated by Myc suggest that 
further work into the role of Myc and its downstream targets in peripheral nerve repair may be 
an interesting area of future research. 
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 Runt-related transcription factor 1 (RUNX1) 
Runx1 was identified as a significantly up regulated transcription factor in the GSEA of our in vivo 
RNAseq data (p<0.01). Runx1 or acute myeloid leukaemia 1 protein (AML1) is a transcription 
factor that regulates the maturation of hematopoietic stem cells. It is also known to play a key 
role in the development of unmyelinated sensory neurons (Liu and Ma, 2011; Lallemend and 
Ernfors, 2012). Runx1 has recently been found to contribute to neurofibroma formation seen 
with neurofibromatosis type 1; Runx 1 over expression was seen at the mRNA and protein levels 
in mouse neurofibromas and inhibition of Runx1 in vitro decreased neurofibroma sphere 
formation (Li et al., 2015). This suggests that characterising Runx1 expression following nerve 
injury may provide interesting results.   
 
 Oct 1 transcription factor 
Of the transcription factors targets which GSEA revealed to be significantly down regulated in 
the SC of the distal nerve, Oct1 was found to be significant (FDR<0.25). Oct 1 is a ubiquitously 
expressed transcription factor with many downstream targets. It has been found to serve as a 
sensor of cell stress and via cAMP is shuttled from the nucleus to the cytoplasm in response to 
cell stress (Zwilling et al., 1994).  Oct1 is a member of the POU family of transcription factors, 
another member of this family, Oct6, is known to be an important regulator of myelination in SC 
(Kawasaki et al., 2003), this family of transcription factors have a common DNA binding domain 
(POU domain) therefore it may be the case that the reported down regulation of Oct1 may 
actually be reflecting changes in Oct6 expression which would be expected to be downregulated 
following nerve transection. However Oct1 can bind to the TATA box binding protein in the 
transcription factor IID (TFIID), the TATA binding protein was also found to be significantly down 
regulated in the SC from the distal nerve (p<0.01). It is reported that c-Jun binds to TATA-binding 
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protein-associated factor-1 (TAF1) which causes a reduction in TFIID driven transcription (Lively 
et al., 2001). This may suggest that some of the actions of c-Jun activation following nerve injury 
may be mediated via down regulation of Oct1 and TATA binding protein therefore loss of 
interaction with TFIID. This may be a potential area of future research. 
 
 Integrins 
Integrins are transmembrane receptors which facilitate interactions between cells and 
extracellular matrix and mediate signals from the extracellular matrix to modify cell behaviour. 
The beta 4 integrin subunit has long been reported to be expressed by both mature myelinating 
SC and SC exposed to cAMP in culture and to fall rapidly after nerve injury (Feltri et al., 1994). It 
comes as no surprise therefore that GSEA showed the integrin 4 and A6B1_A6B4 integrin 
pathways to be significantly downregulated (FDR<0.25) in SC from the distal nerve compared to 
the intact. Interestingly Feltri et al reported that the beta 1 integrin subunit levels did not fall 
after nerve injury and incidentally noted that they may rise (Feltri et al., 1994), our work has 
supported this observation as the Integrin1 pathway and the integrin A9B1 pathway were 
significantly up regulated in SC from the distal nerve (FDR<0.25). The integrin beta 1 subunit is 
known to be essential for radial sorting during development (Feltri et al., 2002). This indicates 
that nerve injury may cause a switch in integrin expression from B4 subunit to B1 subunit which 
may be an interesting area to examine. 
 
 Epithelial mesenchymal transition (EMT) genes 
GSEA analysis of our data showed enrichment of genes associated with the EMT (FDR<0.01).  . 
EMT is a process in which epithelial cells lose their relationship with their surrounding cells and 
acquire the migratory and invasive properties of mesenchymal stem cells. Loss of E cadherin is 
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thought to be fundamental in EMT and in our samples E cadherin was downregulated more than 
fivefold in the distal nerve. Several signalling pathways thought to induce EMT, such as TGF-beta, 
FGF, HGF and notch, (Wang et al., 2010) are also thought to be key player in the reprogramming 
of  mature SC to a repair SC following nerve injury . EMT plays a key role in development, wound 
healing and cancer metastasis. The migratory ability of SC following nerve injury plays a key role 
in axonal guidance, suggesting that this EMT switch of SC is also fundamental in peripheral nerve 
repair. GSEA also showed that there was enrichment of genes associated with extracellular 
matrix interaction (n=8, FDR<0.02) and downregulation of groups of genes associated with cell 
contact and adhesion (n=3, FDR<0.25) in the SC of the distal sample as compared to the intact 
which fits with the migratory properties the SC develop following nerve injury. In 2010 Arima et 
al., suggested that EMT played a key role in the development of neurofibromas caused by the 
loss of neurofibromin (Arima et al., 2010). Recently SC  have been shown to have the ability to 
induce EMT in salivary cystic adenoid carcinoma cells (Shan et al., 2016) which may suggest that 
factors released by SC act in an autocrine fashion to promote EMT. This suggests that EMT genes 
could provide key therapeutic targets for enhancing peripheral nerve repair and treating SC 
associated tumours in the future. 
 
In summary we developed a method of extracting SC specific RNA from sciatic nerves and used this 
method to look at the transcriptional changes between SC in intact nerves and SC in the distal end of 
nerves 6 days after transection, using RNAseq. These results have highlighted several potentially 
interesting areas to study to further our knowledge of peripheral nerve regeneration following 
injury.  
Unfortunately, due to time constraints, it was not possible to sequence RNA from the SC of distal 
nerves at different time points following nerve injury. However, our preliminary data has suggested 
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the concentrating on time pints within the first 72 hours following nerve injury with a later time 
point at 6 days would potentially give the most informative results. 
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4.2  In vitro repair assay 
We aimed to develop an in vitro dedifferentiation assay to use as a high throughput means of 
analysing potential key genes found to be differentially regulated in SC in vivo following nerve injury. 
We have shown that, following cAMP induced differentiation of SC in culture, it is possible to 
enhance the dedifferentiation response known to occur upon cAMP removal, with the addition of 
NRG and 10% FCS to the media. 
 
We have demonstrated that the mRNA levels of the differentiation SC markers P0 and MBP decrease 
and PMP and periaxin significantly decrease, and that the dedifferentiated SC genes  N-cadherin 
increase and cJun, p75 NTR and sox 2 increase significantly (p<0.05) when cAMP is removed from 
the media and NRG and 10% FCS is added (see figure 22). Only the downregulation of PMP and 
periaxin was also significant in SC treated with cAMP removal. Additionally the protein levels of krox 
20 and P0 are decreased to a greater extent than seen with removal of cAMP alone (see figure 23) 
and the protein levels of GFAP and N-cadherin are increased in the dedifferentiated SC group 
compared to the cAMP removal group (see figure 24). We have also shown that these NRG and FCS 
treated cells also regain proliferative properties, this was not seen in SC where cAMP was removed 
(see figure 25).  
 
NRG appears to have opposing actions; during development not only is SC interaction with axonal-
bound NRG essential for SC survival, proliferation and directed migration at the SC precursor stage it 
also is the principle factor involved in SC myelination later in development, and axons lacking NRG1 
type III leads to hypomyelination of the nerve (Taveggia et al., 2005). The  addition of NRG to 
SC/DRG co-cultures has demonstrated that soluble NRG1 type II is sufficient to induce demyelination 
and promote dedifferentiation of SC (Zanazzi et al., 2005) and addition of NRG1 to injured nerves 
facilitates nerve repair (Chen et al., 1998). Syed et al., have shown that these opposing actions may 
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be down to the concentration of NRG1; at low concentrations it has a myelin promoting effect while 
at higher concentrations it inhibits myelination (Syed et al., 2010).   
 
To assess how closely our in vitro dedifferentiation assay recapitulated the transcriptional changes 
seen in SC in vivo following nerve injury, we went on to send  samples of cAMP treated SC 
(differentiated) and SC treated with cAMP then NRG and 10% FCS (dedifferentiated) for RNAseq. The 
normalised RNAseq data gave results for a total of 10124 known genes (26405 genes in total) and 
significant changes (p<0.05) between the differentiated and dedifferentiated groups were seen in 
6121 known genes.   
 
When comparing the GSEA results of functional groups of genes enriched in the dedifferentiated SC, 
10/13 (76.9%) groups that were significantly enriched in the dedifferentiated cells (FDR <0.25) 
overlapped with functional groups found to be enriched in SC from the distal nerve (figure 28a). 3/12 
(25%) of functional groups of genes enriched in the differentiated SC overlapped with the functional 
groups found to be enriched in SC from the intact nerve (figure 28b).  
 
GSEA showed that, as seen with the in vivo RNAseq samples, there was significant overlap of genes 
down regulated the dedifferentiated SC (compared to differentiated SC), with the genes with 
reduced expression in the nerve of the hypomorphic krox 20 mouse (Le et al., 2005) (as compared to 
WT nerve) (figure 27 and 28(b)). When looking at genes up regulated in the nerve of the 
hypomorphic krox20 mouse the overlap of genes was not as great; 18/87 (20%) genes were up 
regulated in the dedifferentiated SC and 7 (8%) of these also overlapped with genes up regulated in 
the distal nerve in our in vivo samples (figure 28 a). 
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When comparing the genes differentially expressed in the dedifferentiated SC compared to the 
differentiated SC 36/84 (43%) were also found to be differentially expressed in rat nerves following 
crush injury when compared to intact nerve (Bosse et al., 2006), of these 21 (25%) were also 
differentially expressed in the distal nerve 6 days following transection compared to intact nerve 
(figure 29). However, Bosse et al. use the whole nerve rather than isolating SC, therefore the 
changes in gene expression reported in this paper may be due to changes in fibroblasts or 
inflammatory cells, therefore we would not expect those gene changes to overlap with the 
expression profile seen in our in vitro and in vivo data as these are SC specific. 
 
The above suggests that the SC dedifferentiation assay we have developed shares some common 
features with the SC reprogramming following nerve injury in vivo. Due to the complex nature of the 
environment of the wounded distal nerve, involving SC interactions with fibroblasts, regenerating 
axons, vessels, inflammatory cells etc, it would be virtually impossible to completely recreate the SC 
reprogramming seen in vivo, in vitro. However the similarities seen between the differentiated SC in 
vitro and the intact nerve in vivo and those seen between the dedifferentiated SC in vitro and the SC 
from the distal nerve in vivo show that this dedifferentiation assay would be a useful first screening 
tool for assessing novel targets found in the analysis of the in vitro work. 
 
 
 
 
 
120  
5. Future Work 
As a next step it would be interesting to perform RNAseq at earlier time points after nerve 
transection. This would give us a temporal view of the reprogramming the SC undergoes following 
transection. Looking at one time point is merely taking a snapshot and may miss key factors which 
regulate the process initially or have are switched on later in the process. Figure 11 shows that by 24 
hours there is already down regulation in the mRNA levels of some myelin proteins and up 
regulation of dedifferentiation markers, it therefore would be important to have a time point earlier 
than 24 hours to catch these early transcriptional changes. When we looked at the protein 
expression of p75NTR, we saw that expression began at the proximal end of the distal nerve at 36 
hours and by 60 hours post sciatic nerve transection, the entire length of the nerve examined 
showed expression of this repair SC marker (figure 12). This suggests that the key events which 
regulate the transition of a mature myelinating SC to a dedifferentiated SC following nerve injury 
occur early in the process meaning that the majority of the time points which would provide useful 
information for a temporal analysis of SC reprogramming should focus on the first 72 hours following 
nerve injury. As events are likely to change as nerve repair progresses and the wound site becomes 
more mature it would be interesting and informative to also have a later time point, around 6 days 
to compare the early changes to.    
 
Studies using microarray (Bosse et al., 2006) and deep sequencing (Yi et al., 2015) technology have 
looked at  various early and late time points following nerve injury, but SC were not specifically 
analysed in either of these cases. Bosse et al reported that most genetic up or down regulation was 
transient and changed over time (Bosse et al., 2006). This reiterates the need for a SC specific, 
temporal overview of the process, with early and late time points.  
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Shue et al have reported that reprogramming of SC occurs in a wave like fashion down the distal 
nerve starting at the tip (Shue at al., 2000), our data (figure 12) supports this. Although by 6 days 
(the time point we used in our study) it is likely all the SC in the distal nerve would have underdone 
reprogramming, as evidenced by protein expression of p75NTR seen down the entire length of the 
distal nerve. This may be something to consider in the future if earlier time points are analysed as 
sequencing SC from the entire length of the distal nerve may mask key genetic changes if only the SC 
at the tip of the nerve are undergoing reprogramming. A single cell sequencing approach  at 
different areas of the distal nerve  might be a way to overcome this. 
Once SC specific RNA from several early and a late time point had been collected (e.g. RNA from the 
SC of the distal end of nerves 18 hours, 36 hours, 54 hours, 72 hours and 6 days following nerve 
transection) and sequenced, we would use genome wide co-expression analysis to identify key hub 
genes. We would focus on novel transcription factors identified and screen a number of these using 
the in vitro dedifferentiation assay we have developed; inducing the SC in culture to over or under 
express the target genes identified and analyse this effected the differentiation response seen when 
NRG and FCS is added to the cells . Over a longer time frame it may be possible to breed mouse lines 
with a conditional knock out of target genes specifically in the SC, and to asses nerve repair in these 
animals.  
 
It may also be possible to look at expression of any genes identified in peripheral nerve sheath 
tumour samples from humans, following a tissue bank application. This translational aspect of the 
work would assess if the genes found to be key players in peripheral nerve repair may also provide 
useful therapeutic targets or prognostic indicators in tumours derived from SC. 
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Appendix A 
RIN values for the groups of nerves used for RNAseq. Each group included 3 pooled nerves. 
Nerve RIN 
Intact 1 7.7 
Intact 2 7.1 
Intact 3 7.5 
Distal 1 7.5 
Distal 2 7.5 
Distal 3 8.1 
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Appendix B 
Genes which are differentially regulated in the hypomorphic krox 20 nerve when compared to 
nerves from WT mice (Le et al., 2005) which are also differentiailly regulated in our in vivo (SC from 
the distal nerve 6 days following transection when compared to SC from intact nerves) and in vitro 
(NRG/FCS dedifferentiated SC when compared to cAMP treated differentiated SC) RNAseq data. 
Differentially regulated in Hypomorphic Krox 20 and in vivo data 
Differentially regulated in Hypomorphic Krox 20 and in vitro data 
Differentially regulated in Hypomorphic Krox 20, in vivo data and in vitro data 
Tenascin C UHRF1 UHRF1 
Cyclin B2 RNA binding motif 3 RNA binding motif 3 
Cyclin D1 High mobility group AT hook 2 High mobility group AT hook 2 
Neuron navigator2 Ribonucleotide reductase M2 Ribonucleotide reductase M2 
CDC 28 protein kinase regulatory 
subunit 2 Phosphodiesterase 8A Phosphodiesterase 8A 
Collagen type 18, alpha 1 Chemokine ligand 2 Chemokine ligand 2 
Myristoylated alanine rich protein 
kinase C substrate 
Pleckstrin homology domain 
containing family O member 1 
Pleckstrin homology domain 
containing family O member 1 
UHRF1 CD44 CD44 
RNA binding motif protein 3 Kinesin family member 22 Kinesin family member 22 
Coactosin-like F actin binding protein 1 SOX2 CD9 
5’nucleotidase domain containing 2 
Protein phosphatiase regulatory 
subunit 14 Carbohydrate sulphotransferase 2 
Cell devision cycle 20 Histone deacytalase 2 ELOVL6 
TCF19 
Haematological and neurological 
expressed 1 EPH receptor B6 
High mobility group AT hook 2 Coronin 1C Fatty acid desaturase 1 
Protein regulator of cytokines 1 
Brain abundant membrane attached 
signal protein 1 
Farnesyl-diphosphate 
farnesyltransferase 1 
Topoisomerase 2 alpha Activating transcription factor 3 FGF1 
Kinesin family member 11 
Myristoylated alanine rich protein 
kinase C substrate GJB1 
CKS1B Enhancer of zeste homolog 2 3-Hydroxyl-3-methylglutaryl CoA 
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Differentially regulated in Hypomorphic Krox 20 and in vivo data 
Differentially regulated in Hypomorphic Krox 20 and in vitro data 
Differentially regulated in Hypomorphic Krox 20, in vivo data and in vitro data 
MAD2L1 ETS1 Isopentenyl diphosphate delta isomerise 1 
Ribosomal Protein L13A Cell adhesion molecule L1 IL16 
Ribonucleotide reductase M2 CD55 LIM and calponin homology domains 1 
Ki-67 CD9 Lysyl oxidase 
Polo like kinase 1 Carbohydrate sulfotransferase 2 MBP 
Phosphodiesterase 8A Clathrin light chain B Microsomal glutathione S transferase 3 
Tumour necrosis factor receptor superfamily member 21 CMTM6 MPZ 
Sperm antigen with coiled domains 1 EF hand domain family member D1 Methylsterol methoxygenase 1 
Cyclin A2 ELOVL6 Mevolonate decarboxylase 
Retinoblastoma like 1 EMI domain containing 1 Nuclear receptor subfamily 4 group A member 2 
CXC chemokine receptor 4 EPH receptor B6 Nuclear receptor binding protein 2 
Structural maintenance of chromosome 22 Fatty acid desaturase 1 PMP22 
EPH receptor A5 Farnesyl diphosphate farnesyltransferase 1 Periaxin 
Basic leucine zipper and W2 domains 2 FGF1 Sodium voltage gated channel alpha subunit 7 
INCENP Ferritin heavy chain 1 Semaphorin 3B 
Chemokine ligand 2 Gap junction B1 Sirtuin 2 
H2A histone family member Z HMGCR Solute carrier organic anion transporter family member 3A1 
Cyclin B1 3-hydroxy-3-methylglutaryl CoA reductase Synuclein alpha 
Endothelin receptor type B Isopentenyl diphosphate delta isomerise 1 TCDD inducible poly (ADP-ribose) polymerase 
Aurora kinase A IL16 Transmembrane protein 30A 
High mobility group protein B2 Inositol triphosphate 3 kinase B Transmembrane protein 40 
Tripartite motif containing 59 LIM and calponin homology domains 1 UDP glycosyltransferase 8 
Nuclear and spindle associated protein 1 Lysyl oxidase  
Non-SMC condensin complex subunit  MBP  
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Differentially regulated in Hypomorphic Krox 20 and in vivo data 
Differentially regulated in Hypomorphic Krox 20 and in vitro data 
Differentially regulated in Hypomorphic Krox 20, in vivo data and in vitro data 
Pleckstrin homology domain 
containing family O member 1 Malic enzyme 1 
 
CD44 
Microsomal glutathione S transferase 
3 
 
Karyopherin alpha 2 MPZ  
Kinesin family member 22 Methylsterol methoxygenase 1  
Baculoviral IAP repeat containing 5 Mevolonate decarboxylase  
ADAM10 N acytyl transferase 2  
Adenylate kinase 3 
Nuclear receptor subfamily 4 group A 
member 2 
 
CD9 Nuclear receptor binding protein 2  
Cyclin dependent kinase inhibitor 1A 
Phosphoinositide 3 kinase regulatory 
subunit 1 
 
Ceramide synthase 2 PMP22  
Carbohydrate sulfotransferase 2 Periaxin  
Claudin 5 Prostoglandin D2 synthase  
24 dehydrocholesterol reductase Ring finger protein 13  
ELOVL6 
Sodium voltage gated channel alpha 
subunit 7 
 
EPH receptor B6 Semaphorin 3B  
Fatty acid amide hydrolase Sirtuin 2  
Fatty acid desaturase 1 
Solute carrier organic anion 
transporter family member 3A1 
 
Farnesyl diphosphate 
farnesyltransferase 1 Synuclein alpha 
 
Farnesyl pyrophosphate synthetase TGF alpha  
FGF1 
TCDD inducible poly (ADP-ribose) 
polymerase 
 
Fibrinogen like 2 Transketolase  
Fucosyltransferase 8 Transmembrane protein 30A  
Gap junction protein B1 Transmembrane protein 40  
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Differentially regulated in Hypomorphic Krox 20 and in vivo data 
Differentially regulated in Hypomorphic Krox 20 and in vitro data 
Differentially regulated in Hypomorphic Krox 20, in vivo data and in vitro data 
Glyoxalase domain containing 4 UDP glycosyltransferase 8  
Guanine nucleotide binding protein 
alpha inhibiting activity polypeptide 1 
  
3-hydroxy-3-methylglutaryl CoA 
reductase 
  
Isopentenyl diphosphate delta 
isomerase 1 
  
Interleukin 16   
LIM and calponin homology domains 1   
Lysyl oxidase   
Lanosterol synthase   
MBP   
Microsomal glutathione S transferase 
3 
  
Multiple PDZ domain protein    
MPZ   
Methylsterol monooxygenase 1   
Metallothionein 3   
Mevalonate diphosphate   
Myosin heavy chain 11   
N-myc downstream regulated 1   
Nuclear receptor subfamily 4 group A 
member 2 
  
Nuclear receptor binding protein 2   
NAD (P) dependent steroid 
dehydrogenase like 
  
Osteoglycin   
Oxysterol binding protein like 5   
Pericentriolar material 1   
Phosphate cytidylytransferase 2   
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Differentially regulated in Hypomorphic Krox 20 and in vivo data 
 
Differentially regulated in Hypomorphic Krox 20 and in vitro data 
 
Differentially regulated in Hypomorphic Krox 20, in vivo data and in vitro data 
PMP22   
Periaxin   
Sodium voltage gated channel alpha 
subunit 7   
Semaphorin 3B   
Serpin family D member 1   
Sirtuin 2   
Solute carrier family 25 member 1   
SLC25A1   
SLC6A15   
SLCO3A1   
Synuclein alpha   
Synuclein gamma   
Thyroid hormone responsive   
TCDD inducible poly (ADP-ribose) 
polymerase   
Transmembrane protein 30A   
Transmembrane protein 40   
UDP glycosyltransferase 8   
.  
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Appendix C 
Genes which are differentially regulated in crushed rat nerves when compared to intact nerves 
(Bosse et al., 2006) which are also differentiailly regulated in our in vivo (SC from the distal nerve 6 
days following transection when compared to SC from intact nerves) and in vitro (NRG/FCS 
dedifferentiated SC when compared to cAMP treated differentiated SC) RNAseq data. 
Differentially regulated in crushed rat nerves and in vivo data 
Differentially regulated in crushed rat nerves and in vitro data 
Differentially regulated in crushed rat nerves, in vivo data and in vitro data 
CD63 CD63 CD63 
CD44 CD44 CD44 
CD9 CD9 CD9 
Integrin beta4 Integrin beta4 Integrin beta4 
CXC chemokine receptor 4 Platelet derived growth factor 
receptor alpha 
FGF 5 
Cyclin dependent kinase 4 FGF 5 GADD45 
FGF 5 GADD45 P75NTR 
Growth arrest and DNA damage inducible Cyclin D3 Epithelial membrane protein 1 
cyclin D1 P75NTR Synaptotagmin IV 
P75NTR Epithelial membrane protein 1 ATP1A2 
Epithelial membrane protein 1 Microtubule associated protein IB ATP1B2 
ILGFBP3 Interferon regulatory factor 1 Cytochrome p450 51  
Prothymosin alpha TGF beta 1 Potassium voltage gated 
channel shaker 1 
Cytochrome c oxidase subunit IV YWHAZ MBP 
Synaptotagmin IV Karyopherin beta P0 
ApoD Cytochrome c oxidase polypeptide 
Vb 
PLP 
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Differentially regulated in crushed rat nerves and in vivo data 
Differentially regulated in crushed rat nerves and in vitro data 
Differentially regulated in crushed rat nerves, in vivo data and in vitro data 
ATPase Na+/K+ transporting subunit alpha 2 Synaptotagmin IV Nestin 
ATPase Na+/K+ transporting subunit beta 2 Arachidonate 12-lipoxygenase Periaxin 
Cytochrome p450 51  ATPase Na+/K+ transporting 
subunit alpha 1 
PMP 22 
Fatty acid binding protein 5 ATPase Na+/K+ transporting 
subunit alpha 2 
plasmolipin 
Potassium voltage gated channel shaker 1 ATPase Na+/K+ transporting subunit beta 2 
Long chain acyl-CoA synthatase 
2 
MBP Cytochrome p450 51   
P0 Potassium voltage gated 
channel shaker 1 
 
PLP sortilin  
Nestin ADP ribosylation factor 6  
Periaxin MBP  
PMP 22 P0  
plasmolipin PLP  
Carbonic anhydrase III Nestin  
Long chain acyl-CoA synthatase 2 Periaxin  
Carboxypeptidase Z PMP 22  
Ribosomal protein L5 plasmolipin  
Ribosomal protein L10a Plasminogen activator 1  
Ribosomal protein L18 Lipoprotein lipase  
Ribosomal protein S24   
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Appendix D 
Genes which are differentially regulated in both the hypomorphic krox 20 nerves when compared to 
WT nerves (Le et al., 2005) and crushed rat nerves when compared to intact nerves (Bosse et al., 
2006) which are also differentiailly regulated in our in vivo (SC from the distal nerve 6 days following 
transection when compared to SC from intact nerves) and in vitro (NRG/FCS dedifferentiated SC 
when compared to cAMP treated differentiated SC) RNAseq data. 
 
Differentially regulated in Hypomorphic Krox 20, crushed rat nerves  and in vivo data 
Differentially regulated in Hypomorphic Krox 20, crushed rat nerves and in vitro data 
Differentially regulated in Hypomorphic Krox 20, crushed rat nerves in vivo data and in vitro data 
CD44 CD44 CD44 
CD9 CD9 CD9 
CXC chemokine receptor 4 MBP MBP 
Cyclin D1 P0 P0 
MBP Periaxin Periaxin 
P0 PMP 22 PMP 22 
Periaxin   
PMP 22   
